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ABSTRACT 
Rapid diagnostic tests, such as lateral flow immunoassays may enable diagnostics in 
resource poor areas, thus improving health outcomes by helping to control and 
eliminate infectious diseases. This thesis focuses on the development of sensitive tools 
for the rapid diagnosis of three infectious diseases prevalent in resource poor areas: 
hepatitis C, pertussis and malaria. For malaria and hepatitis C, rapid diagnostic tests 
with improved sensitivity could help in ongoing efforts to eliminate the diseases. For 
pertussis (whooping cough), a field-usable rapid serodiagnostic test would help in 
disease surveillance and control.  
New methods to enhance the sensitivity of lateral flow immunoassays include pre-
concentrating the sample before the immunoassay takes place, controlling the flow of 
reagents in the lateral flow strip to allow more complex assays and using high-sensitivity 
luminescent instrument-read labels. All the above methods involve trade-offs between 
the sensitivity, complexity, and affordability of the test. 
In publication I of this thesis, immunoassays for anti-HCV antibodies were developed 
using a single multiepitope protein antigen and a luminescent europium-chelate label. 
In II and III, quantitative lateral flow immunoassays utilizing luminescent europium 
nanoparticle labels were developed and assessed. The results obtained with patient 
samples using the lateral flow immunoassay for anti-pertussis antibodies (II) correlated 
well with a traditional enzyme immunoassay. In IV, an higly sensitive lateral flow 
immunoassay utilizing up-converting nanophosphor labels was developed for 
Plasmodium falciparum infection i.e. malaria, and the test performance was evaluated 
with P. falciparum culture samples. The analytical sensitivity of P. falciparum detection 
was improved up to 250-fold as compared to a standard lateral flow test. 
The results of the publications included in this thesis show that the use of intrument-
read luminescent labels in rapid lateral flow immunoassays allows the development of 
highly sensitive and quantitative point-of-care tests, which could be used in-resource 
poor areas. Particularly, an ultrasensitive test for the detection of P. falciparum could 
detect asymptomatic carriers of the malaria parasite and thus support malaria 
elimination efforts.
Tiivistelmä 
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TIIVISTELMÄ 
Pikadiagnostiikka-testit, kuten lateraalivirtaus-immunomääritykset mahdollistavat 
diagnostiikan käytön köyhillä ja eristyneillä alueilla, mikä auttaa kontrolloimaan ja 
hävittämään infektiotauteja. Tämä väitöskirja käsittelee kolmen infektiotaudin 
pikadiagnostiikkaa: hepatiitti C , hinkuyskä ja malaria. Herkemmät pikadiagnostiikka-
testit erityisesti malarialoiselle ja hepatiitti C –infektioille voisivat auttaa yrityksissä 
hävittää nämä taudit. Lisäksi vieritestaukseen soveltuva pikatesti hinkuyskälle auttaisi 
taudin valvonnassa ja helpottaisi taudin leviämisen estämistä. 
Lateraalivirtaus-immunomääritysten herkkyyden parantamiseksi on kehitetty useita 
menetelmiä. Näihin kuuluvat näytteen konsentrointi ennen testin suorittamista, 
määrityksen komponenttien virtauksen kontrollointi ja luminoivien mittalaitteilla 
luettavien leimojen käyttö. Kaikki nämä metodit edellyttävät kompromisseja kehitetyn 
testin herkkyyden, helppokäyttöisyyden ja edullisuuden välillä. 
Väitöskirjatyön ensimmäisessä julkaisussa kehitettiin immunomäärityksiä HCV vasta-
aineille käyttäen multiepitooppiproteiini-antigeenia ja luminoivaa europium-
kelaattileimaa. Toisessa ja kolmannessa julkaisussa kehitettiin luminoivia europium-
nanopartikkeleita käyttäviä kvantitatiivisia lateraalivirtaus-immunomäärityksiä. 
Toisessa julkaisussa kehitetty hinkuyskän vasta-aineita tunnistavaa lateraalivirtaus-
immunomääritys korreloi hyvin potilasnäytteillä perinteisen entsyymi-immuno-
määrityksen kanssa. Neljännessä julkaisussa kehitettiin herkkä käänteisviritteisiä 
nanopartikkelileimoja käyttävä lateraalivirtaus-immunomääritys Plasmodium 
falciparum malarialoisen havaitsemiseksi verestä. Kehitetty testi oli noin 250 kertaa 
herkempi havaitsemaan malarialoisia kuin aikaisemmin käytetyt lateraalivirtaustestit. 
Tämän väitöskirjatyön tulokset osoittavat, että käyttämällä mittalaitteilla luettavia 
leimoja lateraalivirtaus-immunomäärityksissä voidaan kehittää erittäin herkkiä 
kvantitatiivisia pikatestejä resurssiköyhille alueille. Erittäin herkkää malaria-pikatestiä 
voitaisiin erityisesti käyttää havaitsemaan myös malarialoisen oireettomat kantajat ja 
täten tukemaan malarian hävittämisohjelmia. 
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1 INTRODUCTION 
Infectious diseases are a significant burden to the health care systems, especially in the 
poorest countries. In vitro diagnostics can help lower the burden by guiding correct 
treatment for individual patients and by helping to map and control the spread of 
infections. However, in resource-poor areas access to reliable diagnostic testing is very 
limited and lack of access to diagnostic tests impedes health improvement.1 
From the diagnostics point of view, resource-poor areas or settings can be defined as 
areas with little to no access to healthcare resources, laboratory diagnostics in particular. 
Resource-poor settings exist in many countries, for example in remote areas or disaster 
zones where the normal healthcare system cannot function. However, the most 
extensive resource-poor settings are found in countries that do not have a developed 
healthcare system with comprehensive access to central clinical chemistry laboratories 
due to country-wide lack of resources2. The World Bank divides countries into low, 
lower-middle, upper-middle and high income groups, based on gross national income3. 
Most often the countries with significant resource-poor settings are in the low or lower-
middle income groups. I will use these income groups, instead of the ill-defined term 
developing countries, throughout this thesis. 
The lateral flow (LF) immunoassay (LFIA) can provide simple and accurate infectious 
disease diagnostics of at the point-of-care with low cost4. The structure and function of 
a typical LFIA is presented in Figure 1. The first LFIAs for infectious disease detection 
in low-income countries were developed for HIV, tuberculosis and hepatitis B5. Later, 
tests important for low-income countries have been developed for infectious diseases 
such as influenza6, meningitis7, chlamydia8, ebola9, syphilis10, hepatitis C11, and perhaps 
most importantly, malaria12. 
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Figure 1. The structure and function of a typical lateral flow immunoassay. (A) The structure of a 
lateral flow immunoassay strip. The setup presented here is used for malaria assays and consists of (1) 
buffer pad for applying running buffer, (2) conjugate/sample pad where the label conjugate is dried 
and the whole blood sample is added, (3) analytical membrane with the capture antibody immobilized 
on the test line and a secondary antibody immobilized on the control line, (4) absorbent pad. (B) 
When the assay is run, the blood sample is added to the sample pad and buffer to the buffer pad. The 
liquids then flow with the reconstituted label conjugate by capillary action through the porous 
nitrocellulose analytical membrane. A sandwich of label conjugate, analyte and capture antibody 
forms on the test line and unbound label conjugate is bound on the control line, forming visible lines. 
A visible signal on the test line means the test is positive, while all valid tests should have a visible 
signal from the control line. The absorbent pad absorbs excess liquids, which maintains the capillary 
flow. 
While the term LFIA is well defined, the term rapid diagnostic test (RDT) is more 
ambiguous. The EU defines RDTs as being in vitro diagnostic devices, which involve 
non-automated procedures and give a fast result13. In malaria diagnostics, RDT refers 
to diagnostic tests that are inexpensive, require minimal instrumentation, and are 
easy and quick to perform with minimal training. Typically, malaria RDTs use the 
LFIA format and indeed the terms LF test, LFIA and RDT are used interchangeably. 
In other contexts, the term RDT is used for tests with a short turnaround time but 
requiring laboratory equipment, as opposed to true point-of-care tests14. In this 
thesis, the term RDT is used to refer to tests that are LFIAs or are similar to LFIAs, 
where the heterogenous sandwich immunoassay takes place in a membrane with 
minimal liquid handling by the operator and the test is aimed to be usable in 
resource-poor locations.  
This thesis discusses the development of improved rapid tests for three of the infectious 
diseases: hepatitis C, pertussis and P. falciparum malaria. The sensitivity of these RDTs 
Introduction 
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is improved, particularly through the use of instrument-read luminescent labels. In the 
literature review I will discuss other methods, which can be used to improve the 
sensitivity of RDTs, and the current state of rapid diagnostics for the three diseases.
Review of the literature 
14 
 
2 REVIEW OF THE LITERATURE 
 Malaria diagnostics 
According to the latest World Health Organization (WHO) world malaria report, in 
2016 there were 216 million cases of malaria and 445 000 deaths globally15. After years 
of decreasing morbidity and mortality, the progress in malaria elimination seems to 
have stalled. Improvements in malaria diagnostic technologies would help combat 
malaria, both by improving the outcomes of individual patients as well as by supporting 
efforts to eradicate malaria. 
The malaria parasite, genus Plasmodium, is transmitted by mosquitoes of the genus 
Anopheles. The sexual reproduction of the parasite takes place in the gut of the 
mosquito. An infected mosquito transmits sporozoite forms of the parasite to the 
bloodstream during blood meal (Figure 2). The sporozoites invade hepatocytes starting 
a liver stage, during which merozoites are produced. Some P. vivax and P. ovale parasites 
remain dormant and undetectable in the liver as hypnozoites, causing delayed relapse 
of malaria16, 17. The merozoites then infect red blood cells, reproduce asexually, induce 
cell rupture and infect more red blood cells (blood stage), and in parallel a portion of 
parasites develop into gametocytes that can infect a new mosquito. Symptoms of malaria 
start when the merozoites reach roughly 50 parasites / µl of blood, which corresponds 
to approximately 100 million parasites in blood circulation18. 
Review of the literature 
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Figure 2. Life-cycle of the malaria parasite. The life cycle includes transmission between Anopheles 
mosquitoes and humans as well as life cycles inside both hosts. The life cycle in the human host starts 
with the injection of sporozoites into the dermis by a feeding mosquite. The sporozoites migrate to 
the liver and infect hepatocytes. The infected hepatocytes release merozoites into the blood 
circulation, where they infect red blood cells and start the asexual reproduction cycle. Some infected 
red blood cells produce gametocytes, which can be ingested by a feeding mosquito. During the asexual 
repdoction cycle, the production of the main antigen markers of P. falciparum, histidine rich protein 
2 (HRP2), Plasmodium lactate dehydrogenase (pLDH) and aldolase increase as the ring form matures 
into a trophozoite. Immature P. falciparum gametocytes also contain HRP2, while pLDH and aldolase 
is found in mature gametocytes19. (Figure created with Biorender.com) 
In total, five species of the genus Plasmodium are known to infect humans: P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Of these P. falciparum and P. 
vivax are the most common causes of malaria. Also, monkey-infecting P. knowlesi 
present in Southeast Asia occasionally infects humans20. 
P. falciparum causes the most severe form of malaria and accounts for almost all deaths 
from malaria. It is most prevalent in Africa and is limited to tropical regions21. P. vivax 
is found in parts of Africa, Asia and Latin America and is not as climatically 
constrained22. In fact, P. vivax was probably endemic even in parts of Finland up to the 
beginning of the twentieth century23.  In Asia and Latin America, P. falciparum and P. 
Review of the literature 
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vivax have roughly equal prevalence, while the total malaria prevalence is low compared 
with sub-Saharan Africa22. 
Malaria endemic areas can be categorized by transmission intensity and stability of 
transmission. In high transmission-intensity areas, sub-Saharan Africa and parts of 
Oceania, the entomological inoculation rate (EIR, the number of infectious mosquito 
bites per person per year24) can reach 1000/year25. In these areas, malaria-associated 
deaths occur most often in childhood, whereas infections in adults are commonly 
asymptomatic due to immunity26. In low transmission intensity areas, the EIR is 
typically below one. Stable transmission means constant year-round infections, while 
unstable transmission areas have intense transmission only during the rainy season. 
Low transmission intensity and unstable transmission areas can suffer from malaria 
epidemics when conditions change, and in such occasions symptomatic and severe 
malaria occurs in all age classes18. The transmission characteristics in different areas are 
important considerations when planning the use of diagnostics, either for routine 
diagnosis or supporting an eradication campaign. 
Historically, direct observation of stained parasites from blood by microscopy served as 
the “gold standard” for diagnostic testing of malaria. Microscopy does not require 
electricity and the cost per test is very low. However, testing is time-consuming and 
accurate diagnosis requires extensive training of the microscopist. In laboratory 
conditions with a trained microscopist the detection limit is 4 – 20 parasites / µl, while  
in field conditions the detection limit is often 50 – 100 parasites / µl27. 
RDTs, in practice synonymous with LFIAs, have been used for malaria diagnosis since 
the 1990s28. The shift to the more expensive artemisin-based combination therapies has 
sharply increased the use of RDTs with to minimize the wasteful use of medication29. 
Increasingly, RDTs and other point-of-care diagnostic methods are also helping with 
malaria eradication efforts30.     
2.1.1 RDTs for malaria HRP2 antigen 
The widely used RDTs for malaria diagnosis share the same basic technology of LFIA 
with visual labels12. The most significant differences between the RDTs are in the target 
antigens. By far the most important target antigens are P. falciparum histidine rich 
protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH). 
HRP2 is only produced by P. falciparum and as the name suggests, the amino acid 
composition is 35 % histidine with multiple repeating AHHAAD, AHH and AHHAA 
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epitopes. These allow multiple binding of the same paratope to the same antigen, for 
example when using an IgM binder. This in turn increases the avidity of the binding in 
an immunoassay, thus increasing the sensitivity31, 32. HRP2 is produced inside 
erythrocytes, but is released to the bloodstream upon cell rupture. Since HRP2 is very 
stable in blood, with an approximate half-life of 3 – 4 days, its concentration is not 
affected by the life-cycle of the parasite. This enables detection of HRP2 even when the 
parasites are sequestered into organs and non-detectable by microscopy33. On the other 
hand, the long half-life of HRP2 makes it useless for evaluating the response to anti-
malaria therapy. In fact, HRP2 RDTs can lead to false positive results from patients that 
have recently cleared the parasite34. The persistence of HRP2 in blood leads to false-
positive results with standard HRP2 RDTs for up to 4 – 5 weeks after microscopy-
confirmed parasite clearance35, 36. Interestingly, HRP2 has even been detected from 5,200 
year-old Egyptian mummies37. 
The use of HRP2 as a diagnostic antigen is further challenged by the fact that P. 
falciparum strains lacking the pfhrp2 circulate in Africa, South America and Asia38. 
These strains cause false negative results with tests that rely solely on HRP2 as the 
diagnostic antigen39. There might even be positive selection favoring deletions in regions 
where diagnosis and treatment rely solely on HRP2 RDTs40. P. falciparum also produces 
HRP3, which a high sequence homology with HRP2 and is recognized by some 
antibodies used in HRP2 RDTs41. However, there are strains with concurrent loss of 
both HRP2 and HRP342. All in all, to minimize the risk of false negatives due to mutated 
strains, the RDTs should comprise an additional antigen to HRP2, especially in the areas 
where strains with HRP2 deletions circulate. 
Some studies have also suggested that the different number of epitope repeats of 
different HRP2 types may influence RDT performance43. For example, Jimenez et al. 
found that four out of five tested RDTs recognized the cultured PH1 strain (type C) at 
lower concentrations than either the Benin I (type A) or Santa Lucia (type B) strains44 
However, Baker et al. did not find a correlation between HRP2 type and RDT 
performance in an extensive study of highly polymorphic P. falciparum samples with 
the parasite concentrations equalized to 200 parasites / µl. Altogether, the effect of HRP2 
types on RDT performance is currently considered to be insignificant12, 41. 
Quantitative detection of HRP2 
Typically, malaria RDTs with visual labels are designed to give qualitative results of the 
presence or absence of infection. Is there a need for quantitative HRP2 RDTs? Generally, 
a quantitative immunoassay for an infectious disease can be useful for monitoring the 
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response to treatment, assessing disease severity or improving specificity in high-
prevalence areas. The persistence of HRP2 in blood makes treatment response 
monitoring impractical using this antigen, but potentially useful for the other two 
quantitative applications. Even though there is only a limited correlation between 
parasitemia and HRP2 level in blood45, there seems to be a stronger correlation with the 
severity of infection and disease progression to severe malaria46. In fact, it seems that 
plasma HRP2 concentrations distinguish patients with severe malaria from patients 
with another severe febrile illness better than quantifying parasitemia by microscopy47. 
A possible explanation is that the number of sequestered parasites, invisible to 
microscopy yet producing HRP2, are important in severe malaria48. 
In general, quantitative assessment of HRP2 levels is done with immunoassays in central 
laboratories, and a quantitative RDT could bring the benefits to the point-of-care. Sinha 
et al. showed that even the traditional RDTs can be used in a semi-quantitative fashion 
by testing several dilutions of the same sample, and either quantifying the absorbance 
with a scanner or estimating the line intensity visually49. However, this approach has 
limitations: running multiple dilutions from the sample complicates the test and the 
dynamic range is narrow. Therefore, a simple to perform, yet truly quantitative HRP2 
RDT, would be useful in areas where severe malaria is common. 
Clinical and analytical sensitivities of HRP2 RDTs 
The latest product testing programme by WHO and FIND for malaria RDTs evaluated 
the clinical sensitivity, specificity and other characteristics of a total of 202 RDTs in the 
market. Of the evaluated tests, 32 % detected only P. falciparum and 76 % both P. 
falciparum and non-P. falciparum malaria, with one test detecting only P. vivax. The 
sensitivity evaluation was done with a panel of malaria samples diluted to densities of 
200 and 2000 parasites/µl. The sensitivity of both P. falciparum and P. vivax detecting 
test lines is presented in Figure 3 for 200 parasites/µl dilutions of the wild type samples. 
It must be noted that many RDTs detect P. falciparum also with an anti-pLDH test line, 
so in the case of RDTs with combined HRP2 and pLDH detection, the reported clinical 
sensitivity is a combination of HRP2 and pLDH detection.50 
Review of the literature 
19 
 
 
Figure 3. Clinical sensitivity of P. falciparum and P. vivax detecting RDTs from the WHO product 
testing programme phase 2, calculated from the wild type samples50. In practice, many tests contain 
both P. falciparum and P.vivax or pan-malaria test lines. Although the tests can detect P. falciparum 
also with an anti-pLDH test line, usually the P. falciparum result is from a test line detecting HRP2. 
The two RDTs that detected P. falciparum solely by pLDH are shown as filled circles. In total 400 P. 
falciparum positive samples and 140 P. vivax positive samples were tested. 
A meta-analysis of P. falciparum RDT evaluation studies finds the average HRP2 RDT 
sensitivity 95.0 % and specificity 95.2 %51. The evaluations were typically done against 
microscopy. It is important to note that the clinical sensitivities found in the studies of 
malaria RDTs are affected by the choice of the reference. Evaluations against 
microscopy generally result in higher RDT sensitivities than evaluations done against 
nucleic acid test (NAT) methods, since a NAT can detect low parasitemia asymptomatic 
samples52. Overall, the sensitivities of the best HRP2 RDTs currently available seem to 
be sufficient for detecting symptomatic patients with a parasitemia of >100 parasites/µl 
with a high probability. 
Similarly to the clinical sensitivities, also the analytical sensitivities of HRP2 RDTs vary 
widely. The analytical sensitivity can be evaluated based on two values: the density of 
parasites or the actual HRP2 concentration in the sample. Evaluating the analytical 
sensitivity in terms of parasite densities has the benefit of easy comparison to other 
diagnosis methods such as microscopy and NAT. The drawback is the limited 
correlation between parasitemia and HRP2 concentration in patient samples as well as 
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in cultured sample strains, depending on the strain as well as the duration and phase of 
the infection45. The discrepancy between parasitemia and HRP2 concentration has led 
to some differences in the reported analytical sensitivities of HRP2 RDTs. Marquart et 
al. developed a mathematical model to estimate the production of HRP2 in different 
parasitemias and stages of infection34. After finding HRP2 detection limits ranging from 
6900 to 27800 pg/ml for four RDTs, they concluded that according to the model, the 
best performing RDTs should be able to detect parasitemias of 50 – 100 parasites/µl and 
chronic infections with a minimum parasitemia in the range of 8 to 17 parasites/µl. 
The FIND target product profile for point-of-care diagnosis of submicroscopic P. 
falciparum sets the optimal detection limit requirement at 10 parasites/µl, which 
according to FIND would correspond to 6000 pg/ml53. However, a study of five 
unidentified WHO evaluated, best-in-class, HRP2 RDTs demonstrated analytical 
sensitivities of 400 – 1600 pg/ml for HRP2 with both cultured and recombinant HRP244. 
These detection limits are an order of a magnitude lower than the detection limits 
evaluated by Marquart et al. and would suggest that current tests are already meeting 
the FIND target product profile, even though the estimated parasitemia detection limits 
of the tests are at 50 – 100 parasites/µl34. To further complicate the issue, the HRP2 
detection limit of a single RDT varies widely when tested in different locations with 
actual patient samples54. One possible cause of the observed discrepancies may be that 
the methods used in the evaluations have not been standardized, e.g. HRP2 enzyme-
linked immunosorbent assays (ELISAs), for quantifying HRP2 in the tested samples. In 
order to standardize the evaluations of the analytical sensitivities of P. falciparum RDTs, 
WHO and FIND have recently developed an international standard for P. falciparum 
antigens55. 
An RDT for HRP2 detection with a tenfold improvement in analytical sensitivity as 
compared to the traditional RDTs was recently developed. The limits of detection with 
cultured samples and recombinant HRP2 were 40 – 80 pg/ml and 40 – 125 pg/ml, 
respectively. The corresponding parasitemic detection limit of a cultured strain was 3 
parasites/µl. The test has not yet been evaluated with the new international standard, 
and thus a direct comparison to the analytical sensitivities of the traditional RDTs is 
difficult. Nevertheless, the reported sensitivity is very promising and this test may be 
useful in malaria elimination campaigns, as discussed below.56 
2.1.2 Rapid diagnostic tests for malaria pLDH antigen 
pLDH is an enzyme in the glycolytic pathway of the parasite, which is an important 
metabolic pathway in all Plasmodium parasite species57. The pLDH protein has only a 
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25 – 26 % amino acid sequence homology to human LDHs, which makes it a specific 
marker for malaria parasites. In contrast, the sequence homology of pLDH between 
different Plasmodium species is over 90 % and there are common epitopes between the 
species58. This enables design of RDTs using pan-species monoclonal antibodies 
reacting with the five human-infecting malaria species. On the other hand, careful 
design of an RDT with species-specific monoclonal antibodies also enables the specific 
identification of an infecting species. It is particularly important to differentiate between 
the two most common species, P. falciparum and P. vivax, since the treatments applied 
are significantly different59. Apart from P. malariae, the pLDH amino acid sequence 
does not seem to vary between different strains of a single species, rendering the risk of 
false negative results due to mutated strains small60. 
Taken together, there are RDTs with multiple combinations of different pLDH binder 
test lines as well as HRP2 lines for either the pan-specific detection of all Plasmodium 
species or for the specific determination of an infecting species. Figure 4 shows the 
combinations of test lines used in RDTs. The only malaria species that cannot currently 
be specifically identified by RDTs is P. knowlesi, which can be mistakenly identified as 
P. falciparum or P. vivax, depending on the RDT61. 
 
Figure 4. Combinations of test lines detecting different malaria species in RDTs. Strip A can only 
detect P. falciparum (Pf) malaria. Strips B, C and D can differentiate between Pf and non-Pf malaria 
(Pv = P. vivax, Po = P. ovale, Pm = P. malariae). Strip E can differentiate between Pf and Pv, but 
cannot detect non-Pf or Pv malaria. Strip F with three test lines can differentiate between the major 
species and strip G can detect all species, but not identify the species. Data from19. 
Review of the literature 
22 
 
Clinical and analytical sensitivities of pLDH RDTs 
The WHO and FIND product testing programme has also evaluated the sensitivity of 
RDTs for P. vivax detection with a protocol similar to the P. falciparum RDT 
evaluation50. The RDTs for P. vivax predominantly detect pLDH, and the sensitivity of 
these tests is shown in Figure 3 together with the P. falciparum tests. Also, two tests for 
P. falciparum exclusively detected pLDH and are also shown. 
A meta-analysis of P. vivax and non-P. falciparum detecting RDTs found that the RDTs 
reached clinical sensitivities above 90 % only when the parasitemia of the patient 
samples was above 500 to 1000 parasites/µl62. In contrast, the specificities of the tests in 
all the studies were consistently above 98 %. 
The lower clinical sensitivity of pLDH tests as compared to HRP2 tests has several 
potential explanations. Firstly, P. falciparum parasitemia is typically higher than P. 
vivax, and the fact that HRP2 RDTs are only used for P. falciparum biases the 
comparison of sensitivities between species63. Yet, the sensitivities of the pLDH RDTs 
with P. falciparum are lower than with most HRP2 RDTs. A meta-analysis of studies 
that directly compared HRP2 and pLDH RDTs for P. falciparum, showed the HRP2 test 
to have a pooled sensitivity of 96.3 %, while the pooled sensitivity of the pLDH RDTs 
reached only 82.6 % (Table 1)52. pLDH is produced in smaller quantities than HRP2 by 
P. falciparum, which leads to poorer pLDH RDT analytical sensitivities especially with 
low parasitemia samples64, 62. 
The limited clinical sensitivity of the pLDH RDTs can also be partly explained by their 
lack of analytical sensitivity as compared to the HRP2 RDTs. To evaluate the analytical 
sensitivities of different types of pLDH RDTs, Jimenez et al. tested nine pLDH-based 
RDTs with P. vivax patient isolates, P. falciparum culture samples as well as P. 
falciparum and P. vivax recombinant proteins44. The RDTs comprised three tests 
detecting both P. vivax and P. falciparum pLDH (pan-pLDH), three detecting P. vivax 
exclusively, two detecting P. falciparum, and one detecting P. vivax, P. ovale and P. 
malariae. Overall, the analytical sensitivities for the P. vivax samples ranged from 12.5 
to 25 ng/ml for most of the RDTs tested. The P. falciparum specific RDTs had analytical 
sensitivities ranging from 0.5 to 5 ng/ml for the P. falciparum culture samples. In 
particular, the study pointed out a clear difference in the analytical sensitivities of tests 
for P. vivax pLDH as compared to the analytical sensitivities of the HRP2-based RDTs. 
Similar analytical sensitivities were also reported in another study for pLDH RDTs 
evaluated with diluted P. vivax samples65. One reason for the difference in the analytical 
sensitivities may be the differing avidities of the pLDH and HRP2 binders. The 
Review of the literature 
23 
 
difference in avidity is due to the multiple repeating epitopes of HRP2, which allows for 
very high avidity binding both on the solid-phase and on the particle label31, 32. Secondly, 
the parasites may be produce a lower amount of pLDH as compared to HRP2. 
One advantage of pLDH- over HRP2-based RDTs is the fact that the pLDH-based tests 
do not seem to suffer from the prozone effect (also known as the hook effect). In the 
prozone effect the label and capture antibodies are saturated by a sample from a 
hyperparasitemic patient having a high concentration of the antigen66. With P. vivax 
samples, this can be explained by the typically lower parasitemias compared to P. 
falciparum, but with P. falciparum samples the cause could be the lower production of 
pLDH as compared to HRP2. 
In field studies, the clinical specificity of the pLDH RDTs is typically higher than that of 
the HRP2 RDTs51, 52, 62. The best demonstration of the differences in specificities is the 
aforementioned meta-analysis of head-to-head comparison studies of P. falciparum 
HRP2 and pLDH RDTs, the pooled specificity of HRP2 RDTs was only 86.1 % as 
compared to 95.9 % for pLDH RDTs (Table 1)52.  The observed difference  could be due 
to the longer persistence of the HRP2 antigen in the bloodstream, which would lead to 
false positive results in patients with resolved infections34. On the other hand, the shorter 
half-life of pLDH can affect the clinical sensitivity of the RDTs, since pLDH 
concentration in blood is more prone to variation depending on the life-stage of the 
parasite67, 68, 69. 
Table 1. Pooled clinical sensitivity and specificity of HRP2 and pLDH RDTs from a meta-analysis of 
evaluations of RDTs for P. falciparum52.  
Test type Sensitivity % (95% CI) Specificity (95% CI) 
HRP2 96.3 (95.8–96.7) 86.1 (85.3–86.8)  
LDH 82.6 (81.7–83.5) 95.9 (95.4–96.3) 
2.1.3 Other malaria target antigens 
Aldolase is another glycolytic enzyme of the parasite, with a 60 – 70 % sequence 
homology to human aldolases70. It is also highly conserved between P. falciparum and 
P. vivax71. However, in contrast to pLDH, the clinical sensitivities of RDTs targeting 
aldolases have been unsatisfactory72. One aldolase-targeting RDT for P. vivax was 
evaluated by WHO, and had a clinical sensitivity of 85 % (Figure 3).  Typically, aldolase 
has been included in a two-line test format together with HRP2 to enable P. vivax 
detection. The reason for low sensitivity is likely due to the fact that the amount of 
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aldolase produced by the parasite is too low to meet the analytical detection limits of the 
traditional RDTs. 
High-affinity antibodies have also been generated against P.falciparum and P. vivax 
glutamate rich protein (GLURP), dihydrofolate reductase-thymidylate synthase 
(DHFR-TS) and heme detoxification protein (HDP), but apparently they have not been 
applied in RDTs73. 
2.1.4 RDTs for Glucose 6-phosphate dehydrogenase (G6PD) deficiency 
Tests for the detecting human G6PD deficiency are also critical for malaria treatment 
and elimination. The genetic G6PD deficiency increases the haemolysis of aged 
erythrocytes, which affords a degree of protection against the malaria parasites. Indeed, 
polymorphic G6DP deficiencies are most common in populations of malaria-endemic 
areas, with 8 % of the population in malaria-endemic countries affected, a total of 400 
million people74, 75, 76. The deficiency is X-linked and deficient homozygote and 
heterozygous individuals may have variable levels of G6PD activity depending on the 
exact genotype77. 
Primaquine is a drug of the 8-aminoquinoline type and it is the only drug licensed to 
clear hypnozoites and prevent the relapse of P. vivax infection77. It is thus critical in the 
treatment and elimination of P. vivax. Unfortunately, intensive primaquine treatment 
to clear the dormant parasites can lead to acute hemolysis78. The risk of serious side 
effects in a sizable fraction of the patient population in the absence of practical G6PD 
deficiency testing has led to under-prescription of primaquine, thus hampering the 
efforts to control and eliminate P. vivax77. Primaquine can also be used to reduce the 
transmission of P. falciparum, since it kills gametocytes79. For the best treatment 
outcomes and for the malaria elimination efforts to succeed optimally, at least the P. 
vivax diagnostic RDTs should be complemented by rapid G6PD deficiency testing80 
Point-of-care G6PD deficiency tests are based on measuring the activity of the enzyme, 
which catalyzes the following reaction: 
Glucose 6-phosphate + NADP+ ⇌ 6-Phosphogluconate + NADPH + H+ 
Currently, the most widely used G6PD deficiency test is the fluorescence spot test, in 
which fluorescent reaction product NADPH is detected using UV-light81. It is a 
relatively easy test to perform, but requires laboratory equipment and training. RDTs 
with a membrane containing the substrates and a compound that forms a colored 
substance when reduced by the H+ product have been recently developed82. These tests 
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are as easy to perform as LFIAs, but they only provide qualitative results and often fail 
to detect heterozygous females who have 30 – 40 % of the normal G6PD activity83. 
Altogether, a quantitative G6PD test incorporated into a malaria RDT could be 
particularly useful for malaria elimination campaigns84. 
2.1.5 Role of RDTs in malaria elimination 
WHO has set an ambitious goal of 90 % reduction in malaria incidence rate, and 
elimination of malaria from 35 countries by the year 203085. Malaria elimination refers 
to the removal of malaria transmission from a certain area, while eradication means the 
complete interruption of transmission of human-infecting forms of malaria. Most of the 
efforts are aimed towards the elimination of P. falciparum and P.vivax.86 A major 
challenge in this effort is the long duration of infectivity of the human hosts.  In the case 
of patients with functional acquired immunity, a low-density asymptomatic infection 
can persist for over a year.87, 88. These patients can still infect mosquitoes and are an 
important reservoir for the parasite in low- and medium-endemicity areas89. In fact, in 
many populations most infections are submicroscopic and asymptomatic90. Since these 
individuals can account for 20 to 50 % of malaria transmissions in the pre-elimination 
and elimination settings in regions of low prevalence, identifying these infections 
through active case detection using RDTs, and treating them, would help in elimination 
by interrupting the parasite life-cycle91, 92, 84. 
There are two strategies for eliminating the asymptomatic reservoir: 1) mass drug 
administration (MDA), and 2) mass-screen and treat (MSAT) only the carriers found 
with the screening test. In MDA the entire population is administered medication, an 
artemisin-based combination therapy (ACT) in the case of a P. falciparum infection. 
The key to a successful MSAT campaign is in detecting a sufficient proportion of the 
carriers. Usually, RDTs are used for this purpose.93 However, the analytical sensitivity 
of the current P. falciparum or P.vivax RDTs is not sufficient to detect asymptomatic or 
submicroscopic infections with parasite densities below 100 parasites/µl of blood94. The 
studies of MSAT programmes have indicated that the sensitivity of the current RDTs is 
not sufficient for reducing P. falciparum malaria incidence rate, possibly because they 
detect only 10 – 30 % of the NAT-positive carriers 95, 96, 97. 
The key factors in estimating the probability of MSAT success are: the infectiousness of 
the patients with varying parasitemias, the detection limit of the RDT used, the EIR, and 
the seasonality of malaria transmission in the region98. Parasitemia is correlated with the 
density of gametocytes in patient blood, which positively correlates with the probability 
of infecting a feeding mosquito99. For example, according to mathematical models, an 
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RDT with a sensitivity of 2 parasites/µl used in MSAT campaigns could interrupt 
malaria transmission in an area where the EIR is 4 and transmission is highly seasonal100. 
Lately, a new ultrasensitive, RDT (uRDT) for P. falciparum HRP2  with a detection limit 
close to 2 parasites/µl, RDT (uRDT) for has been developed to improve MSAT 
elimination strategies56. This is a 10-fold improvement to the detection limit of the 
traditional RDTs, and in theory the increased sensitivity should expand the applicability 
of MSAT into areas with EIR ranging from 1 to 4. When the uRDT was compared with 
a standard RDT in several cross-sectional studies of populations from varying endemic 
regions, the uRDT detected approximately twice the number of infections101, 102, 103. 
Despite the improvement, the uRDT still only detects approximately 50 % of the patients 
with gametocytes, which can transmit malaria103. Unfortunately, improving the 
detection limit of the RDTs does not significantly improve the diagnosis of malaria from 
febrile patients, since most of the symptomatic patients have values of 100 parasites/µl 
when they seek medical treatment104. Taken together, another 10-fold improvement in 
the detection limit of RDTs would be necessary to increase the efficacy of MSAT 
campaigns. 
While the control and elimination of the more severe and more common P. falciparum 
are the most urgent issues, the elimination of P. vivax is also necessary. In fact, in 
elimination settings the prevalence of P. vivax decreases less rapidly than P. falciparum. 
This indicates that P. vivax could ultimately become the main barrier to the elimination 
of malaria. Generally, the strategies used for P. falciparum elimination would also be 
applicable to P. vivax. However, three characteristics of P. vivax complicate the 
diagnosis and elimination of this species.63 
First, P. vivax parasitemia is typically lower than that of P. falciparum, since P. vivax 
parasites predominantly invade immature red blood cells. This combined with the lower 
production of the pLDH antigen as compared to P. falciparum specific HRP2 leads to a 
requirement of very high analytical sensitivity for P. vivax RDTs used in MSAT 
programmes.63 
Secondly, P. vivax produces gametocytes at an early phase of the infection, even before 
the symptoms appear105. This increases the need for a highly sensitive RDTs capable of 
identifying these patients before they can infect mosquitoes. Thirdly, the P. vivax 
hypnozoites sequestered in the liver cannot be detected by the current diagnostic tests, 
and thus relapsing carriers can restart the parasite life-cyle after completion of the 
MSAT63. 
Review of the literature 
27 
 
 Pertussis diagnostics 
Pertussis, or whooping cough, is a disease caused by a bacteria, Bordetella pertussis. It is 
highly contagious, and despite widespread vaccinations it continues to be a significant 
source of morbidity. The highest morbidity and mortality rates are seen in infants too 
young for vaccination106. 
In vitro diagnostics of pertussis poses some unique challenges when compared with the 
malaria or hepatitis C diagnostics. While malaria and hepatitis C are blood borne 
infections and their antigens are found in the bloodstream, Bordetella pertussis colonizes 
the respiratory tract106. An additional challenge in pertussis diagnostics are the 
vaccinated individuals, since the protective immunity wanes after several years thus 
enabling infections in vaccinated individuals107. 
Pertussis diagnostics can be divided into methods suitable for early and late stage 
diagnosis or surveillance. Early stage diagnosis is important for diagnosing life-
threatening infections in infants and toddlers in the acute phase, since antibiotic 
treatment is only effective if started within one week after the onset of symptoms. Early 
stage diagnosis is commonly based on bacterial culture or PCR from nasopharyngeal 
swabs or aspirates.108 
For older children and adults, the symptoms are typically mild and unspecified such as 
a prolonged cough. In these cases, the diagnostic testing typically takes place only after 
a long period of coughing. The sensitivity of pertussis PCR tests decrease around two 
weeks after the onset of symptoms, at the time when antibodies become detectable, and 
therefore serological tests are recommended for late stage diagnosis. The serodiagnostic 
testing can be done using either single or paired sample serology. In paired samples 
serology the first sample is taken as soon as possible and the second sample weeks later 
at the convalescence phase. The paired sample serology provides a more accurate 
diagnosis, since the change in the immune response between the samples enables 
differentiation between vaccine- and infection-induced immunity109, 110. Single sample 
serology is nevertheless far more convenient for diagnosis as well as surveillance and 
thus more widely used.107 
2.2.1 Immunoassays for chronic pertussis and surveillance 
The most common immunological diagnostic test for pertussis is an enzyme-linked 
immunosorbent assay (ELISA) for anti-pertussis toxin (PT) antibodies. B. pertussis 
displays several antigens that can be used in immunoassays, the antigens include 
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filamentous hemagglutinin (FHA), fimbria and pertactin. While these antigens are 
produced by several Bordetella species, PT is produced solely by B. pertussis and is 
recommended as the only specific antigen for B. pertussis testing.111 
PT is included in all acellular or whole cell vaccines against pertussis112.  Most adults and 
adolescents in the high-income countries have detectable levels of anti-PT antibodies 
due to the high vaccine coverage and the circulation of pertussis in the adult 
population111. Therefore anti-PT immunoassays need to be quantitative and equipped 
with a cutoff to separate recent natural infections from vaccination-induced or past 
infection immunity. The need for quantitative testing in turn has thus far precluded the 
development of a LFIA for anti-PT testing.  
The WHO 06/140 and 06/142 standards for anti-PT antibody detection have been used 
to set diagnostic cutoffs ranging from 40 to 125 IU/ml113. Laboratories typically use in-
house anti-PT ELISAs and the WHO standards have helped in standardizing the results 
of different laboratories. For normal testing the cutoff is usually 100 to 125 IU/ml, while 
lower cutoffs are used in outbreak situations111. If the anti-PT test is used for an 
epidemiological study, a value higher than 100 IU/ml indicates the patient has had an 
infection within a year, and 50 to 100 IU/ml indicates an infection in the past few years. 
A result below 50 IU/ml can stem from exposure to pertussis several years ago, which 
may lead to an overestimation of the pertussis prevalence in epidemiological studies. 
Since the assessment of the diagnosis solely by anti-PT is never clear-cut, the anti-PT 
result should always be assessed in combination with the patient’s vaccination history 
and possible exposure information.114 
Pertussis burden is the highest in low-income countries, particularly in Africa. In a 
ranking of leading causes for years of potential life lost, pertussis ranked on average 32nd 
in sub-Saharan Africa, 67th globally, and 95th in Western Europe115. Furthermore, there 
are large areas in Africa with lower than 50 % pertussis vaccine coverage116. While the 
morbidity and mortality burden of pertussis can be estimated from hospitalized cases, 
current prevalence estimates for pertussis in Africa are very uncertain117. According to 
WHO pertussis surveillance objectives, laboratory confirmation of suspected cases 
would help in pertussis surveillance, both for better estimates of prevalence and for the 
development of vaccination strategies117, 118. 
To improve the surveillance, an RDT for anti-PT antibodies could be used to 
complement ELISAs in resource-poor areas with limited access to hospital laboratories. 
Line immunoblot tests with antigens immobilized on a nitrocellulose strip are used as 
confirmatory tests for anti-pertussis ELISA and are a step towards portable testing. Line 
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immunoblots can separate between IgG, IgA and IgM responses, and can include several 
antigens in addition to PT. They can also provide a semi-quantitative assessment of anti-
PT levels. 119 However, the use additional antigens or detection of IgA and IgM responses 
do not benefit the sensitivity or specificity, and the interpretation of the semi-
quantitative results of line immunoblots is difficult120. Due to the above the use of line 
immunoblots is not recommended as the sole test for pertussis serodiagnosis121. 
LFIAs, on the other hand, could be used also for anti-PT serodiagnostics. Semi-
quantitative visual LFIAs would face the same problem of interpretation, but 
instrument-read tests can provide rapid quantitative results122. There are thus far no 
published anti-PT lateral flow immunoassays, but qualitative serological LF tests for 
viral infections are widely used123.  
2.2.2 Immunoassays for acute pertussis diagnosis 
The main diagnostic methods for acute phase pertussis infections, PCR and bacterial 
culture, require centralized laboratories124. Therefore, rapid immunoassays would 
improve the acute phase diagnostics in resource-poor areas. Direct detection of the 
bacteria or the secreted PT with immunoassays from the same nasopharyngeal aspirate 
used for PCR and culture could provide a simpler method for acute pertussis 
diagnostics125.  
Already in 1989, Friedman et al. published an interesting dot blot immunoassay for PT 
and demonstrated that PT can be detected from nasopharyngeal aspirates125. The 
analytical sensitivity of the dot blot test was 10 ng of PT per dot and the test recognized 
all six positive nasopharyngeal aspirate samples. However, the study was limited to a 
small number of positive samples, and showed a 12 % false positive rate with presumed 
healthy control samples. No further studies related to this test have been published. 
Capture ELISAs for PT have also been developed, but these are solely used for screening 
cultured B. pertussis isolates for strains that lack this important vaccine 
immunogen126,127. Therefore, their sensitivity with nasopharyngeal aspirates has not 
been studied. Although the evidence thus far is quite limited, the results of the dot blot 
immunoassay study suggest that a more sensitive LFIA for PT could reach sufficient 
clinical sensitivity to be useful in rapid diagnosis of acute pertussis.  
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 Rapid diagnostic tests for hepatitis C virus (HCV) 
HCV is a single-strand positive-sense RNA virus of the family Flaviviridae128. HCV 
infection causes the disease hepatitis C, which develops into a chronic disease in 85 % 
of cases. Acute hepatitis C is asymptomatic in most cases, but the chronic disease leads 
over decades to liver disease, cirrhosis and even liver cancer.129 There are an estimated 
70 million people living with chronic hepatitis C, resulting in 700,000 deaths annually. 
Low- and middle-income countries account for 80 % of this global burden.130, 131 Due to 
the vagueness of symptoms, globally fewer than 20 % of those with chronic hepatitis C 
are aware of the infection, and <1 % in low- and middle-income countries132, 133. 
Hepatitis C is a blood-borne infection and it spreads through contaminated blood 
products, medical procedures and via needle-sharing of intravenous drug users. From 
the Second World War to the 1980s HCV spread widely through transfusions of 
contaminated blood. Currently, in high-income countries transfusion-transmitted 
infections have been practically eliminated by the testing of donated blood, but in low-
income countries iatrogenic infections remain a problem.134 Starting from 2014, 
increased knowledge of HCV molecular biology has led to the revolutionary 
development of directly acting antiviral drugs (DAAs), which provide complete viral 
clearance in nearly 100 % of patients with a single 12 week orally administered treatment 
regimen129. Development of the DAAs has opened the door to the possibility of 
eradicating HCV. In fact, one of the goals of the WHO Global Hepatitis Health Sector 
Strategy is that 90 % of HCV infections would be found and treated by the year 2030135. 
Current hepatitis C diagnostic tests are based on detecting anti-HCV antibodies in 
blood with fourth generation anti-HCV enzyme-immunoassays (EIA)11. Since the HCV 
genome is heterogeneous with six major genotypes, the fourth generation EIAs use as 
test antigens a mixture of recombinant proteins and synthetic peptides recognizing all 
six HCV genotypes136. An anti-HCV positive screening sample is usually confirmed with 
a NAT to ascertain that the infection is active, since anti-HCV antibodies remain for life 
even after virus clearance11. NAT can also be used to identify window period infections, 
meaning early acute phase infections in which viremia is present but the antibodies are 
not yet detectable (Figure 5). Due to the risk of window period donations, testing of 
donated blood with NAT is also routine in blood banks of high-income countries134. The 
risk of anti-HCV negative but NAT positive infections to the blood supply is considered 
to be minimal in countries with effective pre-donation screening of blood donors134. 
Immunoassays for HCV core antigen (HCVcAg) are a possible alternative for NAT, 
since they can also cut up to six weeks from the window period and works as a 
confirmatory test137. 
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Figure 5. Kinetics of HCV markers detectable from patient’s serum. HCV-RNA is detectable at the 
earliest phase through NAT methods. HCVcAg can be detected after HCV-RNA, both in free form 
and later bound with antibodies. The anti-HCV immune response can be detected after a window 
period, which can vary between 4 to 8 weeks137.  
RDTs for anti-HCV antibodies using the LFIA platform are widely used in low-income 
countries, with two of the tests already prequalified by WHO (Table 2)138. WHO 
prequalification of a diagnostic test means it has sufficient quality, safety and 
performance so that WHO can recommend it to be purchased by health services and 
non-governmental organizations and it is also eligible for procurement by UN 
agencies135. 
Table 2. Comparison of some key characteristics of the two WHO prequalified anti-HCV RDTs139, 140. 
Both of the prequalified tests perform well compared with standard EIAs.  
Charateristic SD Bioline HCV OraQuick HCV Rapid Antibody Test Kit 
Year prequalified 2016 2017 
Clinical sensitivity %a (95% CI) 100 (97.8–100)  100 (97.8–100) 
Clinical specificity %a (95% CI) 100 (98.9–100) 99.7 (98.3–100) 
Seroconversion sensitivity indexb +2.0 days + 2.75 days 
Mixed titer panel positivity 15/15 20/25 
Time to result 5 min 20 min 
aSensitivity and specificity were tested against an agreed reference standard 
bAverage sensitivity on four seroconversion panels in comparison with standard EIA 
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Rapid testing for HCV can have a significant impact on the fight against HCV on two 
fronts. First, the availability of rapid tests can improve donated blood safety in low and 
lower-middle income countries. Second, a rapid test capable of detecting an active HCV 
infection without a confirmatory test would allow a one-step detect and treat approach, 
considerably improving HCV eradication efforts. 
2.3.1 Rapid HCV tests for transfused blood 
The challenges for donated blood safety in low-income countries, above all in Africa, 
are severe. Particularly, three problems present in low-income countries all compound 
the risk to the blood supply. First, the blood supply is mainly from family or paid donors 
with a higher infection risk than regular voluntary donors141. Secondly, the prevalence 
of HCV is higher in low- and middle-income countries, further increasing the risk142, 143. 
Thirdly, screening of donated blood may be insufficient, and in the case of HCV is often 
done with anti-HCV RDTs, which therefore have great responsibility to screen out the 
infectious donors (Table 3)141.  
Table 3. The distibution of HCV blood screening tests used in blood banks by WHO region141. The 
majority of countries in Africa rely solely on anti-HCV testing for screening of donated blood and 
many of these tests are RDTs. 
 Number of countries by HCV screening tests used 
Region anti-HCV anti-HCV + HCVcAg NAT 
Africa 31 13 2 
Americas 21 6 4 
Eastern Mediterranean 10 4 5 
Europe 15 5 23 
South-East Asia 8 1 2 
Western Pacific 16 1 7 
 
Is the performance of the current anti-HCV RDTs sufficient for the task of blood 
screening? WHO recommends a minimum clinical sensitivity and specificity of 99.5 % 
for any test for donated blood screening144. Studies comparing the sensitivity of RDTs 
with EIAs or NAT show somewhat contradictory results. In a meta-analysis of 52 studies 
with patient samples, Tang et al. found an overall sensitivity of 99 % for different RDTs 
when compared with EIAs and 97 % when compared with NATs145. The overall 
specificity was 99 %. The analysis by Tang et al. also contained studies that were analyzed 
in an earlier meta-analysis that found similar sensitivities,  supporting the conclusions 
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of the analysis and showing that there have not been any significant changes in available 
HCV RDTs the last few years14. While there was high variability in the sensitivities of 
RDTs from different manufacturers, the now WHO prequalified OraQuick HCV RDT 
and SD Bioline HCV RDT showed consistently good sensitivities and specificities across 
studies14, 145. 
However, two studies of RDTs used in real conditions in blood centers around Africa 
found a much lower than expected sensitivity with a standardized panel of HCV-
positive samples including low antibody titer samples146, 147. The sensitivity of HCV 
RDTs varied from 47 % to 100 %, with the now prequalified SD Bioline HCV RDT 
having an average sensitivity of only 72 %. The studies had two weaknesses: There is a 
large variation between the sensitivities of the same RDT between different blood 
centers, pointing to operator errors as a source of poor sensitivity. Also, the sample 
panels used in the studies were not representative of the local HCV population and 
contained diluted samples. Nevertheless, the studies show that EIA-based blood 
screening does have better sensitivity compared to RDTs in African blood centers and 
HCV RDTs have problems detecting possible low antibody titer samples.  
Anti-HCV RDTs, particularly the WHO prequalified tests, provide a validated cost-
effective alternative to donated blood screening in low-income countries139 140. Anti-
HCV RDTs naturally cannot detect the early-phase window-period infections currently 
detected by NAT or HCVcAg immunoassays. The current HCVcAg immunoassays 
have been shown to be a cost-effective alternative to NAT in window-period testing 
although with a lower sensitivity148. 
It is hypothesized that reliable detection of window-period infections would be more 
relevant in the high-prevalence donor pool of many low and lower-middle income 
countries than in the high-income countries, where the probability of a window-period 
donation is very small149. However, a comparison study of nearly 2000 real blood 
donations in high-prevalence Cameroon tested both with a RDT and an Ag/Ab 
combination immunoassay did not find any window-period donations, and the 
sensitivity improvement of the Ag/Ab immunoassay was simply caused by higher 
antibody-detection sensitivity of the Ag/Ab test150. Nevertheless, a RDT capable of 
screening both for anti-HCV antibodies and HCVcAg could provide improved blood 
safety in low and lower-middle income countries. There are currently no RDTs for 
HCVcAg detection, and the major limiting factor in their development is the very high 
analytical sensitivity required123. The current EIAs for HCVcAg reach analytical 
sensitivities in the low femtomolar range, which is almost impossible to achieve with 
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traditional RDT technologies151. Rapid HCVcAg assays should therefore provide an 
ideal test case for the technologies used to improve the analytical sensitivity of RDTs. 
2.3.2 Rapid HCV tests for single-test and treat 
Since the arrival of the new DAA medications has simplified the treatment of hepatitis 
C, it has become possible to envision a protocol where a single diagnosis of active 
infection is followed by a treatment regimen expected to clear the virus completely from 
the patient152. The simplification of treatment could allow realistic efforts to eradicate 
hepatitis C153. However, in order to have a chance of success, any eradication campaign 
requires a diagnostic test that can detect an active HCV infection rapidly and without a 
confirmatory test154. Since the current HCV RDTs detect anti-HCV antibodies they 
cannot be used as a single-test and treat type test to find active infections requiring 
treatment. There is currently a push to automate and miniaturize HCV NAT 
technologies to provide a rapid test, but a true point-of-care NAT for HCV with results 
from finger-prick whole blood has not been realized153.  
A sufficiently sensitive RDT for HCVcAg could also fulfill the criteria for this type of 
single test, since the core antigen indicates the presence of an active infection and core 
antigen levels correlate with HCV RNA levels155. Current EIAs for HCVcAg have been 
found to be sufficient for clinical decision-making156. The FIND target product profile 
for a point-of-care NAT or HCVcAg test sets the optimal analytical sensitivity to 15 
IU/ml and minimal analytical sensitivity to 1000 IU/ml157. The minimal analytical 
sensitivity criterion corresponds to approximately 3 fM concentration of HCVcAg, 
which is also the detection limit of the best current HCVcAg EIAs. The lower optimal 
limit is especially critical in detecting early pre-seroconversion infections, but a test with 
the acceptable minimal analytical sensitivity would still be able to detect 95 % of  patients 
with an active infection158. For screening and treatment purposes, this is considered 
acceptable. Even so, the few published proof-of-concept LF tests for HCVcAg are still 
far from reaching this sensitivity159, 160. 
 Techniques to improve rapid diagnostic test sensitivity 
The greatest limitation for many RDTs lies in the analytical sensitivity. The most 
popular methods for improving RDT analytical sensitivity are optimizing the affinity of 
the binders used the tests and switching from visually read colloidal gold nanoparticle 
(Au-np) labels to instrument-read labels. The different alternatives to the visually read 
Au-np labels have recently been expertly reviewed by Juntunen161. However, other 
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methods related to sample pre-concentration, visual label enhancement and control of 
the liquid flow on the tests can also improve sensitivity of RDTs. These different types 
of sensitivity enhancement methods are not mutually exclusive and could be used in 
combination to further improve test sensitivity. The parameters influencing the 
formation of the sandwich immunoassay in a lateral flow test format is quite complex 
to model162, but in its simplest form can be considered in the terms of the binding 
constants of the binders: 
𝐾𝐾𝑒𝑒𝑒𝑒 = [𝐴𝐴][𝐵𝐵][𝐴𝐴𝐵𝐵]  
The concentration of the binder B is limited by the background signal caused by excess 
label or the binding capacity of nitrocellulose on the test line. The affinity constant Keq 
can be improved by optimizing the affinity of the antibodies used. The concentration of 
the free ligand A, the analyte, can be increased with sample pre-concentration methods. 
The signal generated from the bound complex AB can be improved by label 
enhancement methods without needing to affect the concentration of AB. Thus,  
cumulative improvements on sensitivity could be achieved by developing these different 
facets of the LF test. 
2.4.1 Sample pre-concentration 
In sample pre-concentration methods, the goal is either to increase the usable sample 
volume on a single lateral flow strip, increase the effective concentration of the analyte 
during the binding reactions, or a combination of these. They can be divided into 
methods to enrich the sample before it starts to flow in the actual LF test and methods 
where the analyte concentration takes place during the flow in the test strip.  
Magnetic particles 
Magnetic particles are a popular tool for enriching the analyte from a larger sample 
volume to a volume suitable for a LF assay. The problem is that binding the analyte to 
magnetic iron oxide particles for separation precludes binding the analyte to the Au-np 
label particles for the LF test. This problem has been circumvented with a mix of Au-np 
and magnetic particles forming a co-aggregate, without the analyte binding directly to 
the magnetic particles. Both the Au-np with bound analyte as well as the iron oxide 
magnetic nanoparticles were coated with a linear coblock polymer. When the Au-np 
conjugated with the tracer antibody and magnetic nanoparticles are mixed with the 
sample containing PfHRP2, the normal Au-np tracer + analyte complex is formed. 
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Then, when free polymer is added and the mixture is heated to 40 °C, the Au-np 
coaggregates with the magnetic nanoparticles. This aggregate can be captured by 
applying a magnet and the supernatant can be removed. The aggregates are re-dissolved 
in buffer and the resulting enriched Au-np + analyte complex can be added to a standard 
LF test format.163, 164 
Nash et al. applied this technique to a HRP2 LF test and achieved a 25-fold enrichment 
of the analyte and a 2.5-fold improvement in the detection limit. A significant advantage 
of this method is that it can be easily applied to different analytes with a streptavidin-
coated Au-np and a biotinylated binder. However, the enrichment phase has many 
pipetting steps , a heating step, and takes 30 minutes to complete.164 
The P. falciparum HRP2 antigen is especially suitable for pre-enrichment protocols, 
since its amino acid composition is 35 % histidine and a chelated divalent metal ion can 
reversibly bind the imidazole functional group of the histidine through metal chelation 
chemistry165. Accordingly, the divalent metal ion chelate (M+2-NTA) can be bound to 
solid phase, the sample exposed to the solid phase, unbound sample washed away and 
the bound and concentrated HRP2 can then be eluted with free imidazole. This 
immobilized metal affinity chromatography principle has been used for histidine-rich 
or histidine-tagged protein purification since 1975166. 
Subsequently, magnetic particles with M+2-NTA surface have been used to develop a 
series of HRP2 enrichment methods165, 167. In the simplest format, the M+2-NTA 
magnetic particles are mixed with the sample for 5 to 30 min, after which they are 
directly transferred to the sample pad of a normal malaria HRP2 RDT, and eluted with 
a test running buffer with added imidazole168. This enrichment achieved a 50-fold 
concentration of the analyte with 70 – 80 % of HRP2 captured from the sample, resulting 
in a 21-fold improvement in sensitivity. This is a relatively simple HRP2 enrichment 
format, which was estimated to increase the cost of a test for only 1 USD on top of the 
0.55 – 1.5 USD per test of normal malaria RDTs. 
An alternative method eliminating the need for magnetic particles is a modified pipette 
tip with M+2-NTA resin. HRP2 capture can be achieved from a larger sample by 
pipetting the sample back and forth through the resin, and then eluted by pipetting in 
imidazole elution buffer and ejecting the eluent to the LF strip. This pre-concentration 
method achieved only a 5-fold improvement in sensitivity, but the pipetting steps take 
only 5 minutes and require nothing more than a modified pipette tip and a standard 
pipette.169  
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Integrated sample pre-concentration 
There are three appealing methods for concentrating the analyte in the LF strip itself. 
The method simplest to implement is an integrated dialysis pad on the LF test strip. The 
sample along with a dialysis buffer rich in polyethylene glycol (PEG) can be added onto 
a semi-permeable membrane in front of the conjugate pad, where the sample is 
concentrated through dialysis for 10 minutes before running the LF test170. This resulted 
in a modest 2-fold improvement in the detection limit. 
A more complex analyte concentration method uses an aqueous two-phase system 
(ATPS) to separate biomolecules and the label into two phases based on their 
hydrophilicity and size. In ATPS, a mixture of a polymer and a salt is separated into a 
polymer-rich and salt-rich phase and larger as well as more hydrophilic biomolecules 
and other larger particles are concentrated in the salt-rich phase171. When an ATPS 
mixture is mixed with a sample and Au-np labels before loading onto an LF strip, the 
phase separation is further enhanced since the PEG-rich phase is held back at the 
beginning of the nitrocellulose, while the PEG-poor phase with the analyte and large 
Au-nps moves through the sample pad and nitrocellulose172. The separation can be 
further enhanced by a thick 3D sample pad, on which phase separation can take place 
before flowing into the nitrocellulose. Au-np tracers binding the analyte can thus be 
concentrated on the leading front of the flow in the LF strip, in practice concentrating 
the analyte from a high volume of sample to smaller volume that flows through the LF 
strip. This ATPS-based concentration method has been used in a malaria pLDH LF test 
to concentrate the sample 10-fold with corresponding 10-fold improvement in the 
detection limit, with a 5-minute pre-incubation and a total assay time of 25 min173 
More recently, ionic liquids have been used in an ATPS concentration system to 
improve the phase separation speed outside the LF membranes. This allows a 5-minute 
sample concentration step before adding the concentrated phase to a normal LF test. 
Thus, the method could be used to improve the sensitivity of current tests without costly 
modifications to the LF strip manufacturing process. Overall, ATPS concentration 
methods still need to be optimized according to the analyte and the sample matrix used. 
Particularly, some antibody-antigen interactions may suffer from the high ionic 
strength of the salt phase where the sample is concentrated.174 
Isotachophoresis 
The most elaborate concentration method, yet also most promising from the sensitivity 
improvement point of view, is the use of isotachophoresis (ITP) to concentrate proteins 
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on a LF strip. ITP is a type of electrophoresis where charged analytes are separated and 
concentrated based on their ionic mobility in a medium.175 
When ITP is used in LF, the sample is introduced into a nitrocellulose with a solution 
of slow moving trailing electrolyte ions. Fast moving leading electrolyte ions are 
introduced to the other end of the nitrocellulose and when an electric current is applied 
the analyte moves through the nitrocellulose and accumulates at the boundary of 
leading and trailing electrolyte ions. The analyte is concentrated from a large volume 
into a narrow plug approximately 100 µm wide.175 When this narrow plug moves over 
the test line capture zone, the effective concentration of the analyte is up to 1000-fold 
higher than in the original sample 176. The electric current can even be decreased when 
the plug is migrating over the test line to increase the efficient reaction time.  
The method has been shown to enable both more sensitive as well as faster LF tests, with 
a 160-fold improvement in the detection limit after 5 minutes of running compared with 
the same assay in a normal LF setup. Even so, the method has not been tested with an 
actual sandwich immunoassay or a biological sample matrix and the electric current 
requires a small battery-powered system. Also, the speed of ITP concentration is limited 
by the heating and evaporation of the sample when using higher electric currents. There 
is nonetheless great potential in this concentration methods and it could be possible to 
combine ITP with an instrument-read LF label, where a simple portable instrument 
could perform both ITP and label detection.175 
2.4.2 Flow control 
Many of the presented methods for improving the sensitivity of RDTs introduce extra 
steps to the LF assay protocol. These steps can be automated or simplified by adding 
manual or automatic flow controls to the LF strip architecture. In a LF strip the flow 
speed of the liquid front is powered by capillary action formed in the porous 
nitrocellulose membrane, described by the Lucas-Washburn equation (1)177, 178: 
𝐿𝐿 =  �𝛾𝛾𝛾𝛾𝛾𝛾 𝑐𝑐𝑐𝑐𝑐𝑐 (𝜃𝜃)2𝜂𝜂     (1) 
Where L is the distance the liquid has penetrated the capillary, 𝛾𝛾 is the surface energy, r 
is the radius of the pores, 𝜃𝜃 is the contact angle between the liquid and the pore wall and 
η is the viscosity of the liquid. Similarly, the flow rate of the fully wetted capillary 
membrane is described by the Darcy equation (2) 179, 178: 
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𝑄𝑄 =  −𝜅𝜅𝜅𝜅ℎ
𝜂𝜂𝐿𝐿
∆𝑃𝑃   (2) 
Where Q is the volumetric flow rate, 𝜅𝜅 is the permeability coefficient that is dependent 
on the porous structure of the membrane, wh is the membrane area, 𝜂𝜂 is the viscosity, L 
the length of the membrane and ΔP the drop in pressure occurring over the length of 
the membrane.  
In a normal LF nitrocellulose membrane it can usually be assumed that the average 
radius of the pores and the nitrocellulose material stays constant, thus r, 𝜃𝜃 and 𝜅𝜅 can be 
assumed to remain constant over the whole length of the LF strip. If all the used liquids 
in a single test are similar, 𝛾𝛾, η and µ can be assumed to stay constant. In this typical 
scenario for a LF test, the flow and timing of the different assay liquids can be 
manipulated simply by the length of the membrane they have to flow through. In its 
simplest form this means that the reaction time of the label and the analyte and the flow 
speed of this complex over the test line can be optimized by situating the test line closer 
or further from the start of the nitrocellulose4. 
The predictable flow speeds of liquids on the porous membrane can also be used to 
automate the sequential steps of a multi-step immunoassay process on the LF strip. For 
example, separate rinse and signal amplification steps can be automatically timed with 
a 2-dimensional paper network (2DPN) so that the end user can only add sample and 
buffer to different wells of the LF strip and start the test (Figure 6A)180. The 2DPN 
format has been used to improve the sensitivity of malaria HRP2 detection 4-fold with 
an Au-np enhancement step without significantly increasing the complexity of the test 
for the end user181, 182. This type of automated timing of assay steps can be also used with 
other signal amplification methods such as silver enhancement of Au-np and enzymatic 
labels that have been used to improve LF sensitivity183, 184, 185. In a further improvement 
to HRP2 2DPN LF tests, a horseradish-peroxidase enzyme label together with 
streptavidin – biotin chemistry was used in the paper network LF format, achieving a 
respectable detection limit of 0.1 ng/ml of HRP2 and 90 min running time186. 
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Figure 6. Flow control methods for LF strips. (A) 2-dimensional paper networks can automate the 
application of different liquids to the LF strip at different time-points. When the three liquids are 
added to the 2PDN strip at the same time, the sample and label will arrive at the test line at time t1, the 
washing buffer at time t1 + t2, and the label enhancer at time t1 + t2 + t3. (B) Wax barriers are relatively 
simple to print to LF strips to slow the flow speed of the liquids at desired points. The barriers slow 
the flow of liquid to the substrate compartment, so that the substrate of the label enzyme arrives to 
the test line after the label enzyme itself. (C) Dissolvable sugar barriers can stop the flow on the strip 
for a pre-defined time, allowing the sample and label to react on the strip. 
One drawback of the 2DPN method is that the manufacturing of the large and relatively 
complicated 2DPN strips may be difficult for the normal LF production lines. Printing 
of wax pillar barriers on the nitrocellulose of a standard LF strip is a simpler to 
manufacture method for increasing the effective distance the liquid has to flow. This 
method has been used to develop an enzymatically enhanced LF immunoassay where 
the flow of the substrate for the enzyme-labeled tracer is automatically delayed by 11 
seconds (Figure 6B).187  
The flow timing of liquids in the membrane can also be manipulated by temporarily 
increasing the viscosity (𝜂𝜂) of the liquid with a dissolvable sugar barrier. A barrier 
formed by printing and drying sucrose in the membrane temporarily increases the 
viscosity of the liquid flow, and thus printed sucrose lines of different saturations can be 
used on 2PDN strips to delay the flow of different components for up to 50 minutes188. 
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This allows more flexible automated multi-step 2PDN strip assays without lengthening 
the side-pads too much (Figure 6C). 
A further issue that can be seen from equations 1 and 2 is that the speed of liquid flow 
in the LF membrane may be affected by variation in sample surface energy and viscosity. 
The viscosity of human blood and urine varies between samples, which can introduce 
variation in the test results189. Flow speed differences caused by sample viscosity 
variation can be circumvented by combining the traditional LF strip with a stronger 
upstream capillary pump in a sealed system190. While this method has not yet been tested 
with real assays, it can equalize the flow of a wide variety of sample types, perhaps 
opening the door to future simple tests capable of incorporating multiple sample types. 
All in all, the key compromise in all these sensitivity improvement methods is the 
proportional decrease of the detection limit against added complexity and added time. 
Typically, more time is required if the volume of sample or the proportion of analyte 
that is separated or captured is increased. Another important open question in many of 
the concentration and flow control methods is how well they would function with actual 
sample matrices such as blood or urine. 
 The impact of RDTs 
2.5.1 Disease burdens 
The practical impact of clinical diagnostics depends on the severity and prevalence of 
the disease the test detects. Regarding the diagnostics discussed in this thesis, the burden 
of the three diseases in disability-adjusted life years (DALY) are presented in Figure 7, 
together with the burden of HIV/AIDS for comparison. DALY as a metric combines the 
life years lost to the disease with the possible reduction in the quality of life due to the 
disability caused by the disease. Malaria, particularly P. falciparum malaria, causes by 
far the heaviest burden and thus improved diagnostics for malaria have the potential for 
the greatest impact133. Particularly, very sensitive malaria RDTs could support malaria 
elimination efforts. Also the advent of DAA medications for HCV has opened the 
possibility of eradicating hepatitis C, and rapid diagnostics can be invaluable in helping 
with this task. Thus far, WHO has prequalified RDTs for the diagnosis of malaria, HIV, 
Hepatitis B, HCV and syphilis (Figure 8). 
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Figure 7. Burden of diseases in low socio-demographic index countries, measured in disability-
adjusted life years per 100 000 persons. Included are malaria, pertussis (whooping cough), combined 
HCV-related diseases (hepatitis C, liver cirrhosis and liver cancer caused by HCV) and HIV/AIDS as 
comparison. Despite a significant decrease, malaria burden is still the highest191. 
 
Figure 8. Cumulative number of WHO prequalified RDTs detecting different diseases. The first RDT 
for malaria was prequalified in 2010. By 2018, there were 14 prequalified RDTs for malaria, 20 for 
HIV, 2 for HCV and 2 for HBV. One HIV RDT prequalified in 2015 included also a test for syphilis138.  
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2.5.2 The ASSURED criteria 
The impact of a developed RDT depends not only on the sensitivity and performance of 
the test, but also on the availability of the test in the places where it is needed the most. 
In order to comprehensively evaluate the relevant qualities of a RDT, WHO has 
developed the ASSURED criteria for the ideal diagnostic test for resource-poor areas192: 
Affordable by those at risk of infection 
Sensitive (few false-negatives) 
Specific (few false-positives) 
User-friendly (simple to perform and requiring minimal training) 
Rapid (to enable treatment at first visit) and Robust (does not require refrigerated 
storage) 
Equipment-free 
Delivered to those who need it 
How do the current diagnostic tests for malaria, pertussis and HCV fit the ASSURED 
criteria? For P. falciparum  as well as P. vivax malaria, many of the currently available 
RDTs have sufficient sensitivity and specificity for case-detection and are affordable, 
rapid, easy to use, equipment free and widely used in resource-poor areas, fulfilling the 
criteria well50. The criteria of sensitivity, specificity, cost and the resulting health 
outcomes have also been modeled for different malaria RDTs to further evaluate their 
suitability for different settings193. When considering tests useful for supporting MSAT 
efforts, the only currently available tests with sufficient sensitivity to detect individuals 
with very low parasitemia are NATs, which are not yet usable for point-of-care. 
In principle, there are RDTs for the screening of anti-HCV antibodies from donated 
blood that fulfill the ASSURED criteria138. However, the discrepancy between 
sensitivities achieved in laboratory and field evaluations of HCV RDTs would suggest 
that even the RDTs that should be simple to use have problems with user-friendliness 
and robustness146, 147. Current RDTs for HCVcAg are far from meeting the sensitivities 
required for accurate diagnosis159, 160. For pertussis, the field of RDTs is in its infancy, 
and tests with any relevance for ASSURED criteria are still in the future. 
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The methods for improving the sensitivity of LF tests have different drawbacks when 
evaluated with the ASSURED criteria. Sample pre-concentration methods have the 
potential to improve the sensitivity of RDTs irrespective of the analyte. In particular, 
efforts have been made to improve the sensitivity of malaria HRP2 RDTs. Although 
most of these methods would not increase the price of the test prohibitively, they 
typically lengthen the running time of the RDT and increase the number of handling 
steps needed.  
Flow control methods such as 2PDN and flow barriers can improve the sensitivity 
without making the RDT more complex for the end-user. However, the concern is that 
these types of modifications require changes in design and manufacturing, making the 
tests less affordable. Also, the multi-step or delayed flow methods almost by definition 
increase the running time of the test.
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3 AIMS OF THE STUDY 
The overall aim of this thesis was to develop rapid point-of-care in vitro –diagnostic 
tests for use in resource-poor areas, using luminescent lanthanide-based labels to 
achieve highly sensitive and quantitative tests in the LFIA format. 
More specifically, the aims were: 
I To develop a simple yet sensitive immunoassay for anti-HCV antibodies, based 
on a multiepitope protein (MEP) containing HCV epitopes, and on luminescent 
europium chelate labels.  
II To develop a quantitative serological LFIA with luminescent Eu-nanoparticle 
labels for the diagnosis of pertussis, which is easy to use and suitable for POC 
environments, and to evaluate this assay against a standardized ELISA with 
patient samples. 
III To develop an ultrasensitive LFIA with luminescent Eu-nanoparticle labels and 
explore the critical parameters of a quantitative LFIA that affect the dynamic 
range, assay duration, simplicity and sensitivity of the test.  
IV To develop a simple to use and ultransensitive RDT for P. falciparum malaria 
HRP2 antigen using the LF platform and luminescent upconverting 
nanophosphor labels, and to evaluate the sensitivity of this test against a 
traditional RDT using visual labels.  
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4 SUMMARY OF MATERIALS AND METHODS 
A brief summary of the materials and methods with some additional information is 
presented here. More complete descriptions of the materials and methods can be found 
in the original publications (I – IV). 
 Photoluminescent reporters 
4.1.1 Europium-chelate labels 
The europium chelate label (I), was an isothiocyanate-modified intrinsically fluorescent 
nonadentate europium chelate. The synthesis and conjugation of the label to tracer 
proteins was done as described by von Lode et al.194   
4.1.2 Europium nanoparticle labels 
The carboxyl modified polystyrene nanoparticle labels containing europium chelates 
were from Thermo Fisher Scientific (USA) (II) and Seradyn (USA) (III). The particles 
used had diameters of 99 nm (II) and 107 nm (III). The goat anti-human IgG (II) and 
mouse monoclonal anti-PSA (prostate specific antigen) 5A10 (III) antibodies were 
covalently conjugated to the active carboxyl groups by NHS-EDC chemistry based on a 
method described by Valanne et al.195.  
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4.1.3 Upconverting nanophosphor labels 
Up-converting nanophosphor (UCNP) reporter particles (RD Upcon®540-L-C1-
COOH, product number 46-05RD, Kaivogen, Finland) were used as reporters in 
publication IV. The particles had a hydrophilic coating with an average thickness of 10 
nm (SD 0.8 nm) and a total diameter of 68 nm (SD 2.7 nm) (Figure 9). The particles 
were covalently conjugated with the anti-HRP2 monoclonal antibody by NHS-EDC 
chemistry, and the conjugated particles were resuspended into storage buffer.    
 
Figure 9. (A) Histogram of the particle size distribution of UCNPs used as labels in publication IV. 
(B) Transmission electron micrograph of the UCNP label particles, magnification 80 000x. The 
average size of the coated particles is 68 nm (SD 2.7 nm). TEM-image and size data courtesy of 
Kaivogen Oy. 
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 Sample panels 
The various sample panels used in publications I, II and IV are summarized in Table 4. 
Publication III used a free-PSA (fPSA) standard diluted in pooled female serum as the 
sample and 11 female sera as the negative samples. 
Table 4. Sample panels used in the original publications. Number of samples positive for the relevant 
infection  
Sample panel Positive 
samples 
Negative 
samples 
Notes Publication 
HCV in-house panel 81 51 
61 of the positive 
samples used for 
double-antigen assay 
I 
Worldwide HCV 
Performance Panel 
WWHV301a 
18 2 
samples from HCV 
genotypes 1 to 4 I 
Worldwide HCV 
Performance Panel 
WWHV302a 
14 1 
samples from HCV 
genotypes 1 to 6 I 
Seroconversion panel 
PHV901a 9 2 
Seroconversion 
samples from single 
patient 
I 
Pertussis panel Ib 
 138 0  II 
Pertussis panel IIb 
 32 28  II 
P. falciparum WHO 
manufacturer’s panel 
5 0 
Cultured parasite 
strains IV 
P. falciparum 
Zeptometrix culture 
panel 
6 0 
Pre-diluted cultured 
parasite strains IV 
Malaria-negative in-
house panel 
0 8 
Assumed parasite-
negative individuals IV 
a Purchased from SeraCare Life Sciences (USA), b Received from Department of Medical Microbiology and 
Immunology, University of Turku 
 HCV immunoassays 
4.3.1 HCV multiepitope protein 
A recombinant multiepitope protein (MEP) containing seven conserved and 
immunodominant epitopes from the non-structural and structural proteins of HCV was 
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designed and produced in E. coli (Figure 10). Briefly, the synthetic gene, codon 
optimized for E. coli expression, was custom-synthesized by Geneart (Germany). The 
gene was subcloned into vectors and expressed in E. coli BL21(DE3) strain. The 
insoluble fractions of the cell lysate were purified in denaturing conditions with Ni-NTA 
affinity chromatography and dialyzed into a solubilizing buffer.  
 
Figure 10. The HCV epitopes in the HCV-MEP. Epitopes from non-structural proteins NS3, NS4 and 
NS5 as well as from the core protein were used. The amino acid position of each of the epitopes in the 
original HCV polyprotein is shown, as well as the genotype origin in brackets. 
4.3.2 Immunoassay procedures 
The HCV MEP was used in both a double-antigen immunoassay and a secondary 
antibody immunoassay. In the both immunoassays, the capture surface consisted of 
streptavidin coated wells with immobilized in vivo biotinylated MEP. In the one-step 
double-antigen immunoassay, the sample and Eu-chelate labeled MEP were then added 
to the well (Figure 11B). The secondary antibody immunoassay was done in a two-step 
format, where the sample is added in the first step, unbound sample is washed away and 
Eu-chelate labeled goat antihuman-IgG was added to the well. After a wash step, the Eu-
chelate luminescence of both immunoassays was then measured with a time-resolved 
luminescence reader. 
 
Figure 11. Formats of the HCV immunoassays. (A) In the two-step secondary antibody 
immunoassay, a labeled antihuman-IgG antibody was used as reporter. (B) In the one-step double-
antigen immunoassay, a labeled MEP was used as reporter. 
NS3(1b) NS4A(3a) NS4A(2b) NS4A(1b) NS4B(1b) NS5A(1a) Core(1b)
1192-1457 1681-1735 1681-1735 1681-1735 1920-1941 2273-2307 1-44
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 Avidity index immunoassay 
An avidity index immunoassay was performed in I and with the pertussis samples of II, 
but the avidity index data for pertussis samples were not included in the publication. In 
an avidity index immunoassay, the antigen-specific antibodies of the sample are first 
bound to the surface capture antigen as in a normal well immunoassay. Then, a 
dissociation step is performed by incubating the wells containing the bound antibodies 
with a chaotropic agent, which dissociates weakly bound antibodies. After a wash step, 
the bound antibodies are detected with a labeled secondary antibody and this signal is 
compared with a signal from the same sample acquired without the dissociation step. 
The ratio between dissociation step signals and normal assay signals is the avidity index. 
In the HCV avidity index immunoassay (I), the dissociation step was performed by 
adding 8 M urea, a relatively strong chaotropic agent, which can be used to detect 
increase of the anti-HCV IgG avidity index for up to 36 months from the start of 
infection196. With the pertussis samples, the avidity index immunoassay was performed 
based on the avidity index immunoassay described by Barkoff et al. in wells coated with 
the PT antigen197. The avidity indexes of 56 patient samples were determined. The 
dissociation step was performed with 30 mM diethylamine as the chaotropic agent and 
with the antihuman-IgG conjugated Eu-np as labels. 
 LFIAs 
LFIAs were performed in II – IV. The assay procedure consists of the preparation of LF 
strips and the actual LF immunoassay procedure.  
4.5.1 Preparation of LF strips 
The LF test strips were assembled on an adhesive plastic support from G&L Precision 
Die Cutting (II, III) (USA) or from Kenosha Tapes (IV) (Netherlands). The parts added 
onto the support included a 10 mm wide buffer pad (IV) (Ahlstrom cotton fiber 238, 
Ahlstrom, Finland), and a sample/conjugate pad of 10 mm wide G041 glass fiber 
(Millipore, USA) (II, III) or 10 mm wide Ahlstrom 8950 glass fiber (IV). The 
nitrocellulose membranes used were Millipore HF90 (II, III), Millipore HF180 (III) and 
LFNC-C-SS22-70 (Nupore, India) (IV), all 25 mm wide. The test and control lines were 
dispensed on the nitrocellulose with the Linomat 5 non-contact printer (Camag, 
Switzerland).  
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For the anti-pertussis LF assays (II), the pertussis toxin (PT) (GlaxoSmithKline, 
Belgium) test line was printed in a 10 mM Tris-HCl buffer (pH 8.0) at a speed of 80 nL/s 
to a density of 200 ng/cm. A control line of rabbit anti-goat IgG (Sigma-Aldrich, USA) 
was printed 8 mm from the test line in the same buffer at a speed of 200 nL/s to a density 
of 400 ng/cm.  
For the PSA LF immunoassay (III), the streptavidin test line was printed in 10 mM 
citrate-phosphate buffer (pH 5.0) at a speed of 100 nL/s to a density of 4000 ng/cm. 
Additionally, a biotinylated PSA capture antibody H117 (University of Turku) was 
printed on top of the streptavidin line in 10 mM Tris-HCl buffer (pH 8.0) at a speed of 
100 nL/s to a density of 250 ng/cm. A control line of rabbit anti-mouse IgG (Dako, 
Denmark) was printed 6 mm from the test line in 10 mM Tris-HCl buffer (pH 8.0) at a 
speed of 200 nL/s to a density of 400 ng/cm.  
For the HRP2 malaria LF immunoassay (IV), the anti-HRP2 PTL3 IgM (National 
Bioproducts Institute, South Africa) was printed in 10 mM Tris-HCl buffer (pH 8.0) 
containing 5 % ethanol and 1 % sucrose at a speed of 50 nL/s to a density of 600 ng/cm. 
A control line of rabbit anti-mouse IgG (Dako, Denmark) was printed 5 mm from the 
test line in 10 mM Tris-HCl buffer (pH 8.0) at a speed of 200 nL/s to a density of 400 
ng/cm.  
After the printing of test and control lines, all LF cards were dried for 2 – 3 h at +35°C, 
then cut into 4.8 mm wide strips and stored in room temperature, protected from 
humidity. For the HRP2 malaria LF strips (IV), 25 ng/strip of UCNP-label conjugate 
was dried onto the conjugate pad in 10 mM Tris-HCl buffer (pH 8) containing 0.1 % 
casein, 2.9 % NaCl, 1 % Triton-X-100m 1 % Tween-20, 0.2 % bovine gamma globulin, 2 
mM KF, 5 % sucrose, 5 % trehalose.  
4.5.2 Anti-pertussis LFIA procedure 
The anti-pertussis LF immunoassay (II) had a four-step procedure, in which the strips 
were sequentially moved to microtiter wells containing the reagents (dip-stick 
procedure). First, 20 µl of 1:250 diluted sample serum was added to the strips, followed 
by a wash step. After this, the label of goat anti-human IgG conjugated Eu-np was added 
to the strips. Finally, a second wash step was performed as before. The total time for 
these steps was 30 min.  
The Eu-np luminescence from dry strips was measured by scanning the test and control 
line areas with measurement points at 0.35 mm intervals with a Victor 3 plate reader, 
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using a 615 nm emission filter. The measurement was time-resolved with a 1200 µs delay 
time, a 400 µs counting window and a duty cycle of 1800 µs. 
4.5.3 fPSA LFIA procedure 
The fPSA LFIA (III) had a two-step dip-stick procedure. First, 10 µl of sample serum 
and together with the label consisting of anti-PSA antibody 5A10 conjugated Eu-np 
were added to the strips. Immediately after this, the strip was washed by adding 20 µl of 
assay buffer. The strips were measured at different time-points with a Victor X4 plate 
reader (PerkinElmer), using a 615 nm emission filter. The measurement was time-
resolved with a 400-µs delay time, a 400-µs counting window and a duty cycle of 1000 
µs. 
4.5.4 Malaria HRP2 LFIA procedure 
The malaria HRP2 UCNP-LFIA had a simple two-step procedure, with the LF strip in a 
cassette. First, 5 µl of sample whole blood was applied to the conjugate/sample pad, then 
80 µl of running buffer was added to the buffer pad. After 20 min, the test and control 
line area of the strip was scanned at 0.2 mm intervals with an Upcon UCNP-reader 
device (Labrox, Finland).  
The traditional visual label HRP2 RDTs (First Response Malaria Antigen test kit, 
Premier Medical Corporation, India) were performed according to manufacturer’s 
instructions and the signal was read visually as well as with an image analysis reader 
(Inme reader, Inme, Finland) and a reflective reader (ESEQuant LR3, Qiagen, 
Germany). 
 LF signal analysis 
With all the anti-pertussis and fPSA assays, the maximum reading from the test line 
peak was considered the signal from the sample. With the malaria HRP2 LF assay, the 
signal was extracted by a formula, where the background signal of the individual strip is 
subtracted from the maximum signal of the test. This background-subtracted signal is 
then divided by the signal of the control line. This ratiometric analysis is illustrated in 
Figure 12A. The equation is: 
𝑆𝑆 = (𝑇𝑇 − 𝐴𝐴 + 𝐵𝐵2 )
𝐶𝐶
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Wherein S is the final signal from the strip, T is the maximum reading from the test line, 
A is the background reading from the nitrocellulose 1 mm before the test line, B is the 
similar background reading 1 mm after the test line and C is the maximum reading from 
the control line. 
Subtracting the luminescence background level of the individual strip from the 
maximum reading from the test line improved the performance of the assay. This is 
because individual strips are in somewhat different stages of UCNP label flow when the 
strips are measured after 20 min, which causes different levels of background (Figure 
12B). 
    
Figure 12. Illustration of LF signal analysis methods. (A) In ratiometric analysis, the ratio of the 
maximum signals of the test and control line is used. (B) In the peak detection and background 
subtraction system, the average signal level from around the test line is automatically subtracted from 
the test line peak signal. This decreases the variation between replicates, as illustrated. The 
background-subtracted peak signals for three replicates are shown in the figure. 
For the anti-pertussis LF assay, the strips were analysed both according to the maximum 
reading from the test line and with ratiometric analysis. When test line readings were 
used directly, the average coefficient of variation between two replicates of a same 
sample was 17.6 %, while with ratiometric analysis the variation was 14.5 %.  
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5 SUMMARY OF RESULTS AND DISCUSSION 
 Immunoassay for hepatitis C antibodies 
In I, a single recombinant multiepitope protein (MEP) was developed and evaluated as 
a diagnostic binder antigen in an anti-HCV antibody immunoassay. Two types of anti-
HCV immunoassays were developed and evaluated: a secondary antibody immunoassay 
and a double-antigen immunoassay, both using fluorescent Eu-chelates as labels. The 
sensitivity of the secondary antibody immunoassay with the in-house and worldwide 
performance panels was 95.6 % (108 / 113 positive samples) and the specificity was 100 
% (58 / 58 negative samples) (Table 5). A “hi-lo” graph showing the separation of 
positive and negative results of both assay types are presented in Figure 13. Three of the 
five false-negative samples of the in-house panel had been categorized as positive with 
both commercial reference assays, while two of the false-negative samples had been 
categorized as positive only with one of the reference assays. With the worldwide 
performance panels, the secondary antibody immunoassay detected all the 32 positive 
samples consisting of all the six major genotypes. 
The double-antigen immunoassay was tested with the same panels as the secondary 
antibody immunoassay, but only 61 of the total of 81 positive in-house panel samples 
were tested due to the larger sample volume required for the double-antigen assay 
required. The sensitivity of the double-antigen immunoassay was 91.4 % (85/93 positive 
samples) and the specificity was 100 % (55/55 negative samples). With the worldwide 
performance panels, the double antigen immunoassay detected 31 out of 32 samples, 
the false negative result was obtained with a weak positive genotype 2a/2c sample.  
The results of the secondary antibody immunoassay with a MEP capture antigen had a 
high sensitivity and specificity, and it recognized all the main HCV genotypes. Taken 
together, the results show that the epitopes chosen for the MEP were sufficiently diverse. 
Furthermore, a single simple-to-produce antigen including several epitopes could be 
used instead of multiple recombinant proteins as an affordable diagnostic intermediate 
in a HCV immunoassay. 
The sensitivity of the MEP-based double-antigen immunoassay was lower than in the 
secondary antibody immunoassay. The issues of double-antigen antibody 
immunoassays are discussed in the avidity of antibody response in immunoassays 
section (Section 5.5.).  
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Table 5. Performance of the two MEP-based HCV assays in the in-house panel.a 
Assay % Sensitivity (95 % CI) % Specificity (95 % CI) 
secondary antibody assay 95.6 (90.0-98.6) 100 (93.8-100) 
double-antigen assay 91.4 (83.6-96.2) 100 (93.8-100) 
a95 % CI: 95 % confidence interval calculated according to the Exact Confidence Interval method (Clopper 
and Pearson, 1934) 
 
Figure 13. The 95 % confidence limits of the positive and negative populations of the anti-HCV 
secondary and double-antigen immunoassays presented in a Hi-Lo graph (adapted from I). 
 Anti-pertussis LFIA 
In II, a LFIA was developed for detecting anti-pertussis toxin (anti-PT) IgG antibodies 
from serum. The developed assay was compared with an in-house standardized ELISA 
with 198 patient samples. Correlation between the pertussis LFIA and the ELISA was 
calculated with 170 of the samples that had measurable anti-PT in the ELISA.  
The correlation between the LFIA and the ELISA as well as two typically used clinical 
cutoffs are shown in Figure 14. The 100 IU/ml cutoff is typically used in standard patient 
testing while a lower 50 IU/ml cutoff can be used during epidemics121. At the 100 IU/ml 
cutoff, the overall agreement between ELISA and LFIA was 157/170 (92 %). The LFIA 
sensitivity compared with ELISA was 63/72 (88 %; CI 77-94 %) and specificity 94/98 (96 
%; CI 89 – 99 %). At the lower 50 IU/ml cutoff, the overall agreement was 150/170 (88 %). 
The sensitivity was 78/93 (84 %; CI 75 – 90 %) and specificity 72/77 (94%; CI 85 – 98%).  
The analytical sensitivity of the LFIA was 20 IU/ml, which is below any clinically relevant 
cutoff. This analytical sensitivity could have been lower with the same LF setup, but the 
100
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0
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dynamic range of the test was optimized for the clinically relevant concentration range so 
that the highest discrimination of samples could be achieved at the 100 IU/ml cutoff.  
The correlation between the developed LFIA and the in-house ELISA was good (R2 = 
0.83, p<.001), considering that there is also variation between different commercial 
ELISA kits120, 198, 199. Naturally, ELISA and LF are two very different types of 
immunoassays. In this case, the assay steps of the ELISA and the developed LFIA are 
identical, with sequential introduction of the sample and the label into the strip with 
wash steps in between. Still, there are two major differences that can cause discrepancies 
between ELISA and LF results. First, the avidity of the antibody response against the PT 
antigen varies between vaccinated and naturally infected patients, as well as during 
affinity maturation in the course of the infection197, 200. The effect of antibody avidity on 
the results is further discussed in Section 5.5.  
Secondly, in the LF strip, the sample has to pass through the porous nitrocellulose 
material while travelling to the capture test line, while in ELISA the liquid-to-solid 
capture interface is much simpler. Therefore, there may be different types of matrix 
interference from the serum samples in these two immunoassay types. 
 
Figure 14. Correlation of LFIA and ELISA results of the positive samples (from II). The LFIA results 
are presented as arbitrary units (AU). The 100 IU/mL cutoff is shown with dashed lines and the 50 
IU/mL cutoff is shown with dotted lines. 
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 LFIA for malaria HRP2 antigen 
In IV, a high-sensitivity LF RDT was developed for P. falciparum HRP2 antigen, using 
photoluminescent up-converting nanophosphor reporter particles. The developed LF 
assay with luminescent labels (UCNP-LF) was compared with a WHO prequalified 
commercial RDT with parasite culture panels.  
The UCNP-LF and commercial RDTs were tested with two panels of culture samples. 
For the Zeptometrix panel, only PfHRP2 concentration information was provided while 
the WHO panel had both parasite density and PfHRP2 concentration information. The 
detection limit with UCNP-LF in PfHRP2 concentration varied from 2 to 40 pg/ml 
(mean 13.5 pg/ml, median 12 pg/ml) with the 11 culture samples of a total of eight 
different P. falciparum strains (Table 6). The detection limit of the commercial RDT 
varied from 400 to 820 pg/ml (mean 625 pg/ml, median 700 pg/ml) with the same 
samples.  
For the five WHO panel samples, also the parasite density values were provided. The 
detection limit of the UCNP-LF in terms of parasite density varied from 0.2 to 2 
parasites/µl (mean 0.8 parasites/µl, median 0.5 parasites/µl) (Table 7). The 
corresponding detection limit of the commercial RDT varied from 20 to 100 parasites/µl 
(mean 48 parasites/µl, median 50 parasites/µl). The sensitivities achieved with the 
commercial RDT corresponded well to the sensitivities of five WHO-evaluated HRP2 
RDTs tested by Jimenez et al. (Table 8)44. Overall, the UCNP-LF had a 50 to 250 –fold 
improved sensitivity compared with the commercial RDT. 
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Table 6. Analytical sensitivities of UCNP-LF and First Response HRP2 RDT in pg/ml of HRP2 in 
Zeptometrix and WHO manufacturer’s panels (from IV). The results for the First Response HRP2 
RDT are shown from both visual inspection and the image analysis based reader. 
Sample type Sample Type 
Test analytical sensitivity, pg/ml HRP2 
UCNP-LF First Response HRP2 
 Visual inspection Inme reader 
Zeptometrix 
culture panel 
FCQ79 A 12a (400) 400a (800)  400 a (8000) 
Benin I A 12 800 800 
Borneo C 12 400 400 
Santa Lucia B 12 800 800 
W2 B 40 800 800 
PH1 C 12 800 800 
WHO 
manufacturer’s 
panel 
US05F Benin I A 2 490 490 
US05F Santa Lucia B 10 420 420 
US08F Nigeria XII B 7 700 700 
US05F FC27/A3 B 20 410 820 
US05F PH1 C 10 450 450 
a Own dilutions, official dilutions in parentheses. The official dilutions of the Zeptometrix culture panel 
FCQ79 samples gave discrepant results, the same concentration were also diluted and tested from the 
highest concentration sample. The Zeptometrix PH1 sample was also tested with own dilutions as a 
comparison, there was no difference between these results.  
Table 7. Analytical sensitivities of UCNP-LF and First Response HRP2 RDT in parasites/µl in WHO 
manufacturer’s panel (from IV). The results for the First Response HRP2 RDT are shown from both 
visual inspection and the image analysis based reader. 
Sample type Sample Type 
Test analytical sensitivity, parasites/µl 
UCNP-LF First Response HRP2  
 Visual inspection Inme reader 
WHO 
manufacturer’s 
panel 
US05F Benin I A 0.2 50 50 
US05F Santa Lucia B 2 100 100 
US08F Nigeria XII B 0.2 20 20 
US05F FC27/A3 B 0.5 10 20 
US05F PH1 C 1 50 50 
Table 8. Comparison of the analytical sensitivities reported by Jimenez et al. for five WHO-evaluated 
RDTs and sensitivities reported in publication IV for the commercial RDT, with both panels. 
    Test analytical sensitivity, pg/ml HRP2 
Sample strain Type Jimenez et al. RDTs WHO RDT Zeptometrix RDT 
Benin I A 800 - 1600 490 800 
Santa Lucia B 800 - 1600 420 800 
PH1 C 400 -800 450 800 
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WHO recommends that malaria RDTs should remain stable even with temperature 
peaks up to 50 °C for a minimum of two to six months201, 202. The UCNP-LF tests 
remained stable for at least five months, when stored at room temperature, +40 °C, and 
at +50 °C. The prozone effect (hook-effect) was tested for the UCNP-LF with 
recombinant HRP2 concentrations up to 1 mg/ml without adverse effects to the test 
result. 
To avoid subjective interpretation of the results from commercial RDT utilizing visual 
labels, the line intensities were observed visually and with an instrument detecting the 
lines with image analysis, and additionally with an instrument with reflective 
measurement. There were small differences between the results from visual examination 
and image analysis (Tables 6 & 7). The observed differences are due to the red coloring 
of the nitrocellulose from lysed red blood cells. In fact, measurement of the commercial 
RDT with the reflective detection instrument was not feasible, since the uneven red 
color on the nitrocellulose caused numerous false positive readings. Examples of strips 
and readings with false positive results are presented in Figure 15. This is a problem 
unique for the malaria RDTs, since lysis of red blood cells is required to release the HRP2 
antigen, as opposed to being filtered at the beginning of the strip in most RDTs. While 
the human eye can see the test line quite clearly even with a colored nitrocellulose, the 
coloring problem should be taken into account when choosing the instruments for 
reading the visual malaria RDTs. 
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Figure 15. Examples of conventional RDT strips with red coloring due to lysed red blood cells. The 
image above shows the strip and the reflectance scanning result of the strip with a reflective 
instrument is shown below. Strips A, B and C are examples of false positive results when read by a 
reflective instrument. Strip D is an example of a true positive result.  
The UCNP-LF assay employs a widely used commercial antibody pair (purchased from 
National Bioproducts Institute (South Africa)) as binders203. Therefore, it is likely that 
the dramatic improvement in the sensitivity of UCNP-LF as compared to the standard 
HRP2 RDT is due to the use of the luminescent UCNP-label in the place of classically 
used labels. The advantages and drawbacks of the luminescent instrument-read labels 
are discussed the Section 5.6.  
Recently, an RDT with visually read labels for HRP2 with improved sensitivity was 
described56. The test had a detection limit of 3 parasites/µl with cultured parasite strains 
and the detection limit with recombinant and native HRP2 varied from 40 to 125 pg/ml. 
Population screening studies with the new test in endemic areas showed that an RDT 
with improved sensitivity is useful for detecting a larger proportion of the parasite 
carriers than the traditional RDTs101, 102. Nonetheless, in screening studies conducted 
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with samples from the endemic population both by the sensitive RDT as well as with 
NAT-methods show that the RDT can detect only about 50 % of the infectious parasite 
carriers103. This suggests that supporting malaria elimination efforts needs even more 
sensitive RDTs. 
 Kinetics of LFIAs 
In LFIAs, the signal from the strip can theoretically be measured at any time-point after 
starting the assay. Naturally, a rapid test would preferably be measured at the earliest 
feasible time-point. However, in practice the detection time is always a compromise 
between the early measurement time and the development of the test line signal. The 
use of instrument-read luminescent labels allows real-time measurement of the 
development of the signal on the LF strip. In III, the accumulation of the label on the 
test line of the LF strip and the resulting increase in measured signal was followed on LF 
strips with a slow (small pore size) nitrocellulose and fast (large pore size) nitrocellulose 
membrane (Figure 16). The accumulation of the Eu-np label reached the maximum 
signal levels were after 17 minutes with the fast Millipore HF75 nitrocellulose as 
compared to 21 minutes with the slow Millipore HF180 nitrocellulose. However, due to 
the faster flow and resulting unfavorable binding kinetics, the detection limit of the assay 
on the faster nitrocellulose increased from 10 pg/ml to 14 pg/ml.  
Overall, the effect of nitrocellulose pore size on the sensitivity and speed of the assay was 
quite limited, at least in this particular case: The flow rate of the fast HF75 nitrocellulose 
was 2.4-fold faster than the slower HF180 nitrocellulose, yet the difference in assay time 
decreased only 4 minutes, from 21 to 17 minutes. Also, the detection limit increased 
only from 10 pg/ml to 14 pg/ml. The measurement time-point for each LF test can of 
course be set to any required time, but there will be a compromise with the detection 
limit of the test. Additionally, in this case the measurement time for a quantitative assay 
needs to be exact, since the calibration of the assay will be done for a specific time-point 
and the signal will be significantly different even one minute before or after the 
calibrated time-point, as can be seen in Figure 16. 
For this reason, in II all the pertussis antibody LF assays were measured after the strips 
had dried overnight and the flow of label particles had ceased. In this way, the large 
number of samples could be analyzed without the measurement time affecting the 
quantitative results. In IV, the measurement time-point of the malaria HRP2 LF assay 
was set to 20 minutes according to the FIND target product profile and the assay was 
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optimized for this time-point 53. The malaria HRP2 LF assay strips can also be measured 
at any time after 20 minutes, so the strips can be stored and measured at a later date.  
 
Figure 16. fPSA LF immunoassay signals with luminescent Eu-np labels at different time-points with 
the fast HF75 (●) and slow HF180 (▲) nitrocellulose membranes (from III). The assay with fast HF75 
nitrocellulose reached maximum signal after 17 minutes (dashed line), while with the slow HF180 
maximum signal was reached after 21 minutes (dotted line). Coefficients of variation with three 
replicates for both test types are shown with empty symbols. 
 Avidity of antibody response in immunoassays 
While affinity refers to the direct binding interaction between two molecules, antibody 
avidity reflects the effective average affinity of the specific antibodies to an immunogen 
as a whole in an immune response204. The avidity of an immune response typically 
increases over time after exposure to the immunogen as the immune response 
matures200. The avidity index can be tested with immunoassay protocols that have a 
dissociation incubation phase, in which a chaotropic agent dissociates the weakly bound 
low affinity antibodies. Since avidity increases during affinity maturation in the acute 
phase of the infection, the avidity index immunoassays can be used to separate recent 
and established infections, for example in the case of HCV and HIV antibody 
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immunoassays205, 206, 207. The avidity of the antibody response is also important for the 
efficiency of the resulting protective immunity, and the avidity index immunoassay can 
be used for studies of immunity, as in the case of P. falciparum malaria208  or pertussis197.  
The avidity of the antibody response in the patient sample panels was investigated in the 
anti-HCV antibody immunoassay (I) and the anti-pertussis antibody LF immunoassay 
(II). In the case of the anti-HCV antibody immunoassay, the goal was to compare the 
effect of sample antibody avidity to the two types of developed assays, the secondary 
antibody immunoassay and the double-antigen immunoassay. The avidity index for the 
in-house panel patient samples ranged from 0.05 to 0.87. The patient samples were 
sorted into low avidity index (<0.3) and high avidity index (>0.5) cohorts according to 
a classification by Hedman and Rousseau209. In the double-antigen immunoassay, the 
low avidity index cohort had a mean signal to cutoff ratio of 2.1 (95 % confidence 
interval: 1.2 – 3.0) and the high avidity cohort a mean signal to cutoff ratio of 42.9 (95 
% CI: 24.2 – 61.6) (Table 9). In the secondary antibody immunoassay with the same 
sample cohorts, the low avidity index cohort had a mean signal to cutoff ratio of 8.0 (95 
% CI: 2.8 – 13.2) and the high avidity index cohort a signal to cutoff ratio of 20.5 (95 % 
CI: 17.7 – 23.2).  
Table 9. The different signal to cutoff ratios (S/Co) of secondary antibody immunoassay in the low 
avidity index (<0.3) and high avidity index (>0.5) patient sample groups. The 95 % confidence 
intervals are shown in brackets. 
Assay 
S/Co in low avidity index 
cohort, AI<0.3 (95% CI) 
S/Co in high avidity index 
cohort, AI>0.5 (95% CI) 
secondary antibody assay 8.0 (2.8 – 13.2) 20.5 (17.7 – 23.2) 
double-antigen assay 2.1 (1.2 – 3.0) 42.9 (24.2 – 61.6) 
The avidity index of the HCV seroconversion panel was also investigated and compared 
between the secondary antibody immunoassay and double-antigen immunoassay 
results (Figure 17). Notably, the secondary antibody immunoassay detected 
seroconversion already 97 days after first bleed where the sample had an avidity index 
of 0.18, the double-antigen immunoassay detected seroconversion only with the sample 
taken 159 days after first bleed, which had an avidity index of 0.53. 
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Figure 17. Signal to cutoff ratios of (A) secondary antibody immunoassay (B) double antigen 
immunoassay, and the avidity index of the positive seroconversion samples (adapted from I). 
These results suggest that the double-antigen immunoassay is vulnerable to low affinity 
antibodies in the patient samples. This is due to the necessity of two independent 
binding events in the double-antigen immunoassay. The antibody needs to bind 
specifically to both the capture and tracer antigen to be detected. In contrast, in the 
secondary antibody immunoassay the antibody can bind bivalently to the capture 
surface, wherein it is recognized by the high-affinity labeled secondary antibody. The 
end result is that the practical avidity of the antibody binding increases with bivalent 
binding, which  in turn decreases the affinity effect of any antibody on the secondary 
antibody immunoassays210 211.  
With the anti-pertussis antibody LFIA, the avidity indexes of the patient samples were 
measured to investigate the samples that had discrepant results between the LFIA and 
ELISA. In the LFIA, the sample antibodies have a very limited time to react with the 
capture PT antigen on the test line, whereas in ELISA the sample incubation time with 
the capture PT is typically hours212. Therefore, there may be a risk that lower avidity 
samples have anomalously low signals in the LFIA as compared to ELISA. However, 
while there was wide variability in the avidity indexes of the patient samples, the four 
discrepant samples did not show dramatically lower avidity indexes when compared to 
the rest of the samples (Figure 18). The results suggest that in this case the LFIA is not 
vulnerable to low AI samples.  
Summary of results and discussion 
65 
 
 
Figure 18. Avidity index of anti-PT antibodies was measured from 56 serum samples. A threshold of 
50% AI (dashed line) was used to determine strong and weak binding. The four discordant samples 
are shown as filled circles. 
In order to simplify the assay protocol for the anti-pertussis LFIA, it could be possible 
to develop a double-antigen LFIA with the PT antigen. In this case the differences in the 
sample avidities could cause larger discrepancies between the double-antigen LFIA and 
ELISA, as indicated by the anti-HCV immunoassay results. Also, the double-antigen 
LFIA would detect the anti-PT IgM and IgA responses in addition to the IgG, further 
weakening the correlation to ELISA.  
 Luminescent labels in RDTs 
Three types of luminescent labels were used in the publications of this thesis. In I a 
europium chelate label was used, while in II and III europium chelate –doped 
nanoparticle (Eu-np) labels were used and upconverting nanophosphor (UCNP) labels 
were used in IV. In I, the luminescent chelate labels were used in place of the enzyme 
labels typically used in well-based enzyme immunoassays. In II, III and IV, the 
luminescent particles were used as labels in LFIAs, replacing the typically used visual 
labels.  
Eu-np are polystyrene nanoparticles doped with Eu-chelate labels. They produce very 
high specific activity signals, since lanthanide chelate fluorescence does not suffer from 
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self-quenching, and can be measured with minimal background fluorescence due to 
their large Stokes’ shift and long-lifetime luminescence213. Eu-np labels have been used 
before to develop quantitative and very sensitive LFIAs.214-220. 
UCNP labels have an inorganic crystal core containing lanthanide ions, which can up-
convert long wavelength infrared radiation to shorter wavelength long-lifetime 
phosphorescence. The resulting anti-Stokes’ shift is not generally found in nature, which 
helps eliminate any background photoluminescence from the LF strip materials or the 
sample. Also, UCNPs can withstand high intensity excitation light, which allows the use 
of high-energy infrared lasers as the excitation source.  Together, these qualities make 
UCNPs an excellent label for high-sensitivity assays221 
The research in this thesis did not attempt to directly compare the sensitivities of 
different types of labels. However, the sensitivity of the UCNP-LFIA (IV) was compared 
with a commercial RDT using visual labels, using the dilutions of P. falciparum malaria 
culture samples. An example of the signal-to-cutoff levels achieved by the two different 
assays with the WHO Benin I culture sample are presented in Figure 19. The signal-to-
cutoff levels of the commercial First Response HRP2 RDT are measured with an 
instrument detecting the test line concentration with image analysis. Overall, the 
UCNP-LF improved the detection limit for P. falciparum HRP2 50- to 250-fold. 
 
Figure 19. Comparison of the signals from WHO Benin I panel sample dilutions. UCNP-LF results 
shown with filled markers, traditional First Response HRP2 RDT using visual labels shown with 
empty markers.  
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It is difficult to directly compare the detection limits achieved by different LFIAs using 
different types of labels. However, an overview of the published detection limits 
converted into molarity can be used to gain a general picture of the sensitivities of 
different label technologies (Figure 20). The fPSA LFIA (III) with Eu-np labels achieved 
a detection limit of 3.5 x 10-13 M, and the HRP2 malaria UCNP-LF (IV) had detection 
limits ranging from 1.3 x 10-12  to 6.7 x 10-14 M depending on the culture sample. 
 
Figure 20. Comparison of detection limits achieved in published LFIAs using different label 
technologies with the detection limits of the fPSA LF assay using Eu-np labels and malaria HRP2 LF 
assay using UCNP-labels. 
Previously described LFIAs utilizing Eu-np reporters for a variety of analytes had their 
detection limits in the 10-12 M range216-219. LFIAs using UCNP-labels have reached 
detection limits ranging from 10-12 to 10-15 M222-225. The detection limits of LFIAs based 
on Au-np labels vary from 10-5 to 3 x 10-11 226. 
For point-of-care applications, a portable, simple and affordable reader is required to 
achieve a feasible field-usable test. Portable readers capable of reading Eu-np LFIAs have 
been developed for both research and commercial use216, 218-222, 227. Similarly, several 
readers for UCNP-LFIAs have been described228-232.  
In addition to the significant improvement in sensitivity, the instrument-read LF assays 
have other advantages over visually read LF assays. An instrument can objectively 
interpret, archive and transmit the results, simplifying the technical aspects of the assay, 
by reducing the requirements for operator experience and removing sources of 
subjectivity and error233. Also, any quantitative LF assay requires an instrument for 
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reading the signal. Luminescent labels are very suitable for quantitative assays since they 
have lower background and wider dynamic range than typical visual absorbance-based 
labels234. 
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6 CONCLUSIONS 
There is a need for more sensitive simple-to-use, yet affordable RDTs, both for routine 
case detection as well as in support of control and eradication efforts. For malaria, the 
current RDTs are widely available, affordable and sufficiently sensitive for passive case 
detection. Nevertheless, more sensitive malaria RDTs are needed to support the 
elimination efforts. The case for HCV RDTs is similar: current RDTs are usable as the 
first screening test, but point-of-care tests, which could help in eradication efforts by 
confirming an active hepatitis C infection are not available. For pertussis, there is a need 
for both serological and direct antigen detection point-of-care immunoassays. 
When considering the techniques to improve LF test sensitivity, the key question is the 
compromise between sensitivity on the one hand and test complexity as well as added 
time on the other. Test complexity includes manufacturing complexities, and increases 
the number of assay steps performed by the end user. The complexities of 
manufacturing can be further divided into more expensive manufacturing of LF strips 
and extra liquid handling equipment, and the need for a separate portable reader for the 
instrument-read labels. 
The main conclusions based on the original publications are presented below. 
I  A single recombinant MEP antigen incorporating different epitopes that is simple 
to produce in E. coli can recognize all different HCV genotypes. A secondary 
antibody immunoassay using the MEP as a capture binder and a luminescent 
europium-chelate label showed a good clinical sensitivity and specificity when 
tested with patient samples. A double-antigen immunoassay with the MEP used 
as capture and as a labeled tracer suffers from low sensitivity with low antibody 
avidity patient samples. 
II The developed pertussis antibody LFIA with luminescent Eu-np labels has a good 
correlation and high sensitivity and specificity when compared to a standard 
ELISA with patient samples. The developed point-of-care LF may be used in 
situations in which a convential ELISA for diagnosis of pertussis is not available, 
such as in resource-poor areas. 
III It is possible to develop an ultrasensitive and quantitative LFIA for fPSA by using 
luminescent Eu-np labels. The LF assay can be simplified to a rapid two-step 
format without a significant loss of sensitivity. 
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IV An RDT for P. falciparum malaria HRP2 with instrument-read luminescent 
UCNP-labels was developed. An up to 250–fold improvement in thedetection 
limit compared with a standard RDT was shown with P. falciparum culture 
samples. The developed LF test is as rapid and simple to use as the traditional 
RDTs. 
In conclusion, the findings of this thesis show that the use of luminescent labels in LF 
immunoassays allows the development of highly sensitive and quantitative rapid tests 
with potential for use in resource-poor areas. The findings particularly show that the 
analytical sensitivity of lateral flow immunoassays can be dramatically improved by 
using luminescent labels. The simplicity and rapidity of the IAs developed were 
particularly demonstrated with the malaria HRP2 LF assay, which is as rapid and easy 
to use as the traditional RDTs.  
The main challenge for the practical usability of these tests in resource-poor areas is the 
need for an affordable, portable and robust reader for the luminescent labels. However, 
this type of a reader is especially feasible for the UCNP-labels, thanks to their robustness 
and unique luminescence properties. The instrument-read tests also provide the 
advantages of objectivity and reliable communication of results. Taken together, the 
tests with instrument-read labels are needed in cases where the current RDTs cannot 
achieve sufficient analytical sensitivity, such as in screening of non-symptomatic 
carriers of malaria parasites, or in cases where a quantitative rapid test is needed to 
replace ELISA, such as in pertussis serology. 
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